0000749647 2026-01-01 2026-09-30 0000749647 2026-11-12 0000749647 2026-09-30 0000749647 2025-12-31 0000749647 us-gaap:SeriesAPreferredStockMember 2026-09-30 0000749647 us-gaap:SeriesAPreferredStockMember 2025-12-31 0000749647 us-gaap:SeriesBPreferredStockMember 2026-09-30 0000749647 us-gaap:SeriesBPreferredStockMember 2025-12-31 0000749647 2026-07-01 2026-09-30 0000749647 2025-07-01 2025-09-30 0000749647 2025-01-01 2025-09-30 0000749647 us-gaap:SeriesAPreferredStockMember 2026-07-01 2026-09-30 0000749647 us-gaap:SeriesAPreferredStockMember 2025-07-01 2025-09-30 0000749647 us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-09-30 0000749647 us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-09-30 0000749647 us-gaap:SeriesBPreferredStockMember 2026-07-01 2026-09-30 0000749647 us-gaap:SeriesBPreferredStockMember 2025-07-01 2025-09-30 0000749647 us-gaap:SeriesBPreferredStockMember 2026-01-01 2026-09-30 0000749647 us-gaap:SeriesBPreferredStockMember 2025-01-01 2025-09-30 0000749647 2024-12-31 0000749647 2025-09-30 0000749647 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0000749647 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2026-06-30 0000749647 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0000749647 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2026-06-30 0000749647 us-gaap:CommonStockMember 2026-06-30 0000749647 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2026-06-30 0000749647 us-gaap:TreasuryStockCommonMember 2026-06-30 0000749647 us-gaap:RetainedEarningsMember 2026-06-30 0000749647 2026-06-30 0000749647 us-gaap:CommonStockMember 2025-06-30 0000749647 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2025-06-30 0000749647 us-gaap:TreasuryStockCommonMember 2025-06-30 0000749647 us-gaap:RetainedEarningsMember 2025-06-30 0000749647 2025-06-30 0000749647 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0000749647 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2025-12-31 0000749647 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0000749647 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2025-12-31 0000749647 us-gaap:CommonStockMember 2025-12-31 0000749647 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2025-12-31 0000749647 us-gaap:TreasuryStockCommonMember 2025-12-31 0000749647 us-gaap:RetainedEarningsMember 2025-12-31 0000749647 us-gaap:CommonStockMember 2024-12-31 0000749647 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-12-31 0000749647 us-gaap:TreasuryStockCommonMember 2024-12-31 0000749647 us-gaap:RetainedEarningsMember 2024-12-31 0000749647 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0000749647 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0000749647 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0000749647 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0000749647 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0000749647 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0000749647 us-gaap:TreasuryStockCommonMember 2026-07-01 2026-09-30 0000749647 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0000749647 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000749647 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000749647 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0000749647 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0000749647 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0000749647 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0000749647 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0000749647 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0000749647 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0000749647 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0000749647 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-09-30 0000749647 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0000749647 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0000749647 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0000749647 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-09-30 0000749647 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0000749647 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0000749647 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2026-09-30 0000749647 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0000749647 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMember 2026-09-30 0000749647 us-gaap:CommonStockMember 2026-09-30 0000749647 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2026-09-30 0000749647 us-gaap:TreasuryStockCommonMember 2026-09-30 0000749647 us-gaap:RetainedEarningsMember 2026-09-30 0000749647 us-gaap:CommonStockMember 2025-09-30 0000749647 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2025-09-30 0000749647 us-gaap:TreasuryStockCommonMember 2025-09-30 0000749647 us-gaap:RetainedEarningsMember 2025-09-30 0000749647 IMNN:PreFundedWarrantsMember 2025-12-31 0000749647 IMNN:PreFundedWarrantsMember 2026-09-30 0000749647 2025-08-07 2025-08-07 0000749647 IMNN:CommonStockWarrantsMember 2026-01-01 2026-09-30 0000749647 IMNN:CommonStockWarrantsMember 2025-01-01 2025-09-30 0000749647 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0000749647 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:OvationTrialsMember 2026-01-01 2026-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:OvationTrialsMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:MRDStudyMember 2026-01-01 2026-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:MRDStudyMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:PlaccineVaccineMember 2026-01-01 2026-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:PlaccineVaccineMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:OtherClinicalAndRegulatoryMember 2026-01-01 2026-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:OtherClinicalAndRegulatoryMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember 2026-01-01 2026-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:NonClinicalRAndDAndCMCMember IMNN:ManufacturingAndClinicalSupplyMember 2026-01-01 2026-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:NonClinicalRAndDAndCMCMember IMNN:ManufacturingAndClinicalSupplyMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:NonClinicalRAndDAndCMCMember 2026-01-01 2026-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:NonClinicalRAndDAndCMCMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember 2026-01-01 2026-09-30 0000749647 us-gaap:OperatingSegmentsMember 2025-01-01 2025-09-30 0000749647 IMNN:NoteAOneMember 2026-09-30 0000749647 IMNN:NoteBMember 2026-09-30 0000749647 us-gaap:SeriesAPreferredStockMember IMNN:SecuritiesPurchaseAgreementMember IMNN:StreetervilleCapitalLLCMember 2026-06-02 2026-06-02 0000749647 us-gaap:SeriesAPreferredStockMember IMNN:SecuritiesPurchaseAgreementMember IMNN:StreetervilleCapitalLLCMember 2026-06-02 0000749647 IMNN:SecuredPromissoryNoteAOneMember IMNN:SecuritiesPurchaseAgreementMember IMNN:StreetervilleCapitalLLCMember 2026-06-02 0000749647 IMNN:SecuredPromissoryNoteBMember IMNN:SecuritiesPurchaseAgreementMember IMNN:StreetervilleCapitalLLCMember 2026-06-02 0000749647 IMNN:SecuritiesPurchaseAgreementMember IMNN:StreetervilleCapitalLLCMember 2026-06-03 2026-06-03 0000749647 IMNN:SecuritiesPurchaseAgreementMember IMNN:StreetervilleCapitalLLCMember 2026-06-03 0000749647 IMNN:SecuredPromissoryNoteBMember IMNN:SecuritiesPurchaseAgreementMember IMNN:StreetervilleCapitalLLCMember 2026-06-03 0000749647 us-gaap:PreferredStockMember 2026-09-30 0000749647 IMNN:SecuritiesPurchaseAgreementMember IMNN:StreetervilleCapitalLLCMember 2026-09-30 0000749647 IMNN:SecuredPromissoryNoteAOneMember IMNN:SecuritiesPurchaseAgreementMember IMNN:StreetervilleCapitalLLCMember 2026-06-03 2026-06-03 0000749647 2026-06-03 0000749647 IMNN:SecuredPromissoryNoteAOneMember 2026-09-30 0000749647 IMNN:SecuredPromissoryNoteAOneMember 2026-09-30 2026-09-30 0000749647 srt:MinimumMember IMNN:SecuredPromissoryNoteAOneMember 2026-09-30 2026-09-30 0000749647 IMNN:SecuredPromissoryNoteAOneMember us-gaap:MeasurementInputOptionVolatilityMember 2026-09-30 0000749647 IMNN:SecuredPromissoryNoteAOneMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0000749647 IMNN:SecuredPromissoryNoteAOneMember 2026-06-03 0000749647 IMNN:SecuredPromissoryNoteAOneMember us-gaap:MeasurementInputOptionVolatilityMember 2026-06-03 0000749647 IMNN:SecuredPromissoryNoteAOneMember IMNN:ExchangeAgreementMember 2026-09-28 0000749647 IMNN:SecuredPromissoryNoteAOneMember us-gaap:SeriesBPreferredStockMember IMNN:ExchangeAgreementMember 2026-09-28 2026-09-28 0000749647 IMNN:SecuredPromissoryNoteAOneMember us-gaap:SeriesBPreferredStockMember IMNN:ExchangeAgreementMember 2026-09-28 0000749647 IMNN:NoteAOneMember 2026-09-28 0000749647 IMNN:NoteAOneMember 2026-07-01 2026-09-30 0000749647 IMNN:NoteAOneMember 2026-01-01 2026-09-30 0000749647 IMNN:NoteAOneMember 2026-09-28 2026-09-28 0000749647 IMNN:NoteAOneMember 2026-06-30 0000749647 us-gaap:SeriesBPreferredStockMember 2026-09-28 0000749647 2026-09-28 0000749647 2026-09-28 2026-09-28 0000749647 IMNN:NoteAOneMember 2026-07-01 2026-09-30 0000749647 IMNN:NoteAOneMember 2025-07-01 2025-09-30 0000749647 IMNN:NoteAOneMember 2026-01-01 2026-09-30 0000749647 IMNN:NoteAOneMember 2025-01-01 2025-09-30 0000749647 IMNN:NoteBMember 2026-07-01 2026-09-30 0000749647 IMNN:NoteBMember 2025-07-01 2025-09-30 0000749647 IMNN:NoteBMember 2026-01-01 2026-09-30 0000749647 IMNN:NoteBMember 2025-01-01 2025-09-30 0000749647 IMNN:NoteAOneMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000749647 IMNN:NoteAOneMember us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-09-30 0000749647 IMNN:NoteAOneMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0000749647 2024-05-15 2024-05-15 0000749647 us-gaap:CommonStockMember IMNN:AtTheMarketOfferingAgreementMember 2026-03-23 2026-03-23 0000749647 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0000749647 srt:MinimumMember 2026-03-31 0000749647 2025-07-25 2025-07-25 0000749647 2025-07-25 0000749647 2025-07-24 0000749647 2025-07-10 0000749647 2025-07-11 0000749647 2025-07-28 0000749647 2025-07-28 2026-07-28 0000749647 IMNN:AtTheMarketOfferingAgreementMember 2026-03-23 2026-03-23 0000749647 IMNN:AtTheMarketOfferingAgreementMember 2026-01-01 2026-09-30 0000749647 IMNN:AtTheMarketOfferingAgreementMember 2025-01-01 2025-09-30 0000749647 IMNN:MayTwoThousandTwentyFiveWarrantExchangeMember 2025-05-12 0000749647 IMNN:MayTwoThousandTwentyFiveWarrantExchangeMember 2025-05-12 2025-05-12 0000749647 IMNN:MayTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-05-23 2025-05-23 0000749647 IMNN:PreFundedWarrantsMember IMNN:MayTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-05-23 0000749647 us-gaap:WarrantMember IMNN:MayTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-05-23 0000749647 IMNN:PlacementAgentsWarrantMember IMNN:MayTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-05-23 0000749647 IMNN:DecemberTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-12-29 2025-12-29 0000749647 IMNN:PreFundedWarrantsMember IMNN:DecemberTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-12-29 0000749647 us-gaap:WarrantMember IMNN:DecemberTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-12-29 0000749647 IMNN:PrefundedWarrantAndWarrantsMember IMNN:DecemberTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-12-29 0000749647 us-gaap:WarrantMember IMNN:DecemberTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-12-29 2025-12-29 0000749647 IMNN:OfficersAndDirectorMember 2026-01-01 2026-09-30 0000749647 IMNN:GrantedUnderTwoThousandEighteenPlanMember IMNN:EquityStockAwardsMember 2026-09-30 0000749647 IMNN:TwoThousandAndEighteenStockIncentivePlanMember 2026-01-01 2026-09-30 0000749647 IMNN:EmployeeStockOptionAndRestrictedStockAwardsMember 2026-01-01 2026-09-30 0000749647 IMNN:EmployeeStockOptionAndRestrictedStockAwardsMember 2025-01-01 2025-09-30 0000749647 IMNN:EmployeeStockOptionAndRestrictedStockAwardsMember us-gaap:ResearchAndDevelopmentExpense 2026-01-01 2026-09-30 0000749647 IMNN:EmployeeStockOptionAndRestrictedStockAwardsMember us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-09-30 0000749647 IMNN:EmployeeStockOptionAndRestrictedStockAwardsMember us-gaap:ResearchAndDevelopmentExpense 2025-01-01 2025-09-30 0000749647 IMNN:EmployeeStockOptionAndRestrictedStockAwardsMember us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-09-30 0000749647 IMNN:TwoThousandAndEighteenStockIncentivePlanMember 2026-09-30 0000749647 IMNN:GrantedUnderTwoThousandEighteenPlanAdoptionMember IMNN:EquityStockAwardsMember 2026-09-30 0000749647 IMNN:GrantedUnderTwoThousandEighteenPlanAmendmentOneMember IMNN:EquityStockAwardsMember 2026-09-30 0000749647 IMNN:GrantedUnderTwoThousandEighteenPlanAmendmentTwoMember IMNN:EquityStockAwardsMember 2026-09-30 0000749647 IMNN:GrantedUnderTwoThousandEighteenPlanAmendmentThreeMember IMNN:EquityStockAwardsMember 2026-09-30 0000749647 IMNN:GrantedUnderTwoThousandEighteenPlanAmendmentFourMember IMNN:EquityStockAwardsMember 2026-09-30 0000749647 IMNN:GrantedUnderTwoThousandEighteenPlanAmendmentFiveMember IMNN:EquityStockAwardsMember 2026-09-30 0000749647 IMNN:GrantedUnderTwoThousandEighteenPlanAmendmentSixMember IMNN:EquityStockAwardsMember 2026-09-30 0000749647 us-gaap:EmployeeStockOptionMember 2025-12-31 0000749647 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0000749647 us-gaap:EmployeeStockOptionMember 2026-09-30 0000749647 srt:MinimumMember 2025-01-01 2025-09-30 0000749647 srt:MaximumMember 2025-01-01 2025-09-30 0000749647 IMNN:LawrencevilleNewJerseyLeaseMember 2023-08-31 0000749647 srt:MinimumMember IMNN:LawrencevilleNewJerseyLeaseMember 2023-08-01 2023-08-31 0000749647 srt:MaximumMember IMNN:LawrencevilleNewJerseyLeaseMember 2023-08-01 2023-08-31 0000749647 IMNN:LawrencevilleNewJerseyLeaseMember 2025-04-30 0000749647 IMNN:LawrencevilleNewJerseyLeaseMember 2026-04-01 0000749647 srt:MinimumMember IMNN:LawrencevilleNewJerseyLeaseMember 2025-04-01 2025-04-30 0000749647 srt:MaximumMember IMNN:LawrencevilleNewJerseyLeaseMember 2025-04-01 2025-04-30 0000749647 IMNN:HuntsvilleAlabamaLeaseMember 2023-01-31 0000749647 srt:MinimumMember IMNN:HuntsvilleAlabamaLeaseMember 2023-01-01 2023-01-31 0000749647 srt:MaximumMember IMNN:HuntsvilleAlabamaLeaseMember 2023-01-01 2023-01-31 0000749647 us-gaap:SubsequentEventMember IMNN:AssetPurchaseAgreementMember IMNN:VoxelDoxTherapeuticsIncMember 2026-10-20 2026-10-20 0000749647 us-gaap:SubsequentEventMember 2026-10-20 0000749647 us-gaap:SubsequentEventMember IMNN:ConsultingAgreementsMember 2026-10-20 0000749647 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-10-27 2026-10-27 0000749647 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-10-27 0000749647 us-gaap:SubsequentEventMember 2026-10-27 0000749647 us-gaap:SubsequentEventMember 2026-10-27 2026-10-27 iso4217:USD shares iso4217:USD shares pure utr:sqft IMNN:Segment false --12-31 Q3 0000749647 10-Q true 2026-09-30 2026 false 001-15911 Imunon, Inc. DE 52-1256615 997 Lenox Drive Suite 100 Lawrenceville NJ 08648 (609) 896-9100 Common stock, par value $0.01 per share IMNN NASDAQ Yes Yes Non-accelerated Filer true false false 6487286 0.01 4039298 8781059 1798851 1942685 5838149 10723744 393696 529936 5039468 687365 984436 50000 50000 5776833 1034436 12008678 12288116 1276747 1392829 1137346 2824646 1344728 444982 406354 34809 4238612 4623829 4884625 263115 602411 9386352 5226240 0.01 0.01 100000 100000 250 250 0 0 3 2251918 0.01 0.01 200 200 120 120 0 0 1 1 1131657 1131657 0.01 0.01 350000000 350000000 6210958 3419652 6210956 3419650 62110 34197 431373320 428410939 -432111495 -421298072 2707514 7147064 2 2 85188 85188 2622326 7061876 12008678 12288116 1792524 1899251 5594487 5291297 1655177 1576577 4951312 5097694 3447701 3475828 10545799 10388991 -3447701 -3475828 -10545799 -10388991 83511 46704 173559 116813 264133 341406 -167643 -167643 45679 67866 -302586 46704 -267624 116813 -3750287 -3429124 -10813423 -10272178 62331 80383 800 800 -3813418 -3429124 -10894606 -10272178 -0.64 -0.64 -1.16 -1.16 -2.01 -2.01 -5.53 -5.53 5947263 5947263 2943655 2943655 5408092 5408092 1855922 1855922 -10813423 -10272178 207112 216830 297071 312805 732238 115895 965123 99040 -167643 67866 70166 188451 -143834 -129436 -2104050 -841351 -10213701 -10239523 70872 276983 -70872 -276983 1292932 6437251 2183579 7105769 10277 3467694 10582280 9894668 297707 -621838 8781059 5872767 9078766 5250929 1200000 274295 68342 250 3 2251918 4665660 46657 430336605 2 -85188 -428361208 4188787 -3750287 -3750287 120 1 1131657 1131658 268504 2685 449247 451932 973000 9730 -9633 97 303792 3038 506734 509772 90367 90367 250 3 2251918 120 1 1131657 6210956 62110 431373320 2 -85188 -432111495 2622326 1717502 17175 416373961 2 -85188 -413646098 2659850 -3429124 -3429124 70448 704 704 543265 5433 3467387 3472820 222227 2223 1497777 1500000 330397 3304 -13581 -10277 10767 108 98932 99040 1667 16 16 -211305 -211305 2896273 28963 421213171 2 -85188 -417075222 4081724 3419650 34197 428410939 2 -85188 -421298072 7061876 -10813423 -10813423 250 3 2251918 120 1 1131657 3383579 625480 6255 1288381 1294636 1609114 16091 -17794 -1703 556712 5567 959556 965123 732238 732238 250 3 2251918 120 1 1131657 6210956 62110 431373320 2 -85188 -432111495 2622326 966712 9667 411122863 2 -85188 -406803044 4244298 966712 9667 411122863 2 -85188 -406803044 4244298 -10272178 -10272178 70448 704 704 1032752 10328 6426219 6436547 482550 4826 3462869 3467695 330397 3304 -13581 -10277 10767 108 98932 99040 2647 26 26 115869 115869 2896273 28963 421213171 2 -85188 -417075222 4081724 2896273 28963 421213171 2 -85188 -417075222 4081724 <p id="xdx_806_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zIX9WF2omgn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1. <span id="xdx_82E_zSVUnjnCMWvi">Business Description</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imunon, Inc. (“Imunon,” the “Company,” “we,” “our,” or “us”) is a clinical-stage biotechnology company focused on developing its non-viral DNA technology to advance a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. The lead modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials, including one Phase 2 clinical trial (OVATION 2), and is currently being studied in a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_808_eus-gaap--BasisOfAccounting_zduCaGrSZPDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2. <span id="xdx_829_zuDgC6uDUYpf">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements, which include the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. All significant intercompany balances and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the opinion of management, all adjustments, consisting only of normal recurring accruals considered necessary for a fair presentation, have been included in the accompanying unaudited condensed consolidated financial statements. Operating results for the three months and nine months ended September 30, 2026, and 2025 are not necessarily indicative of the results that may be expected for any other interim period(s) or for any full year. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 31, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amounts reported in the Company’s financial statements and accompanying notes. Actual results could differ materially from those estimates. Events and conditions arising subsequent to the most recent balance sheet date have been evaluated for their possible impact on the financial statements and accompanying notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant Accounting Policies</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our significant accounting policies are more fully described in Note 1 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 31, 2026. See Note 3 to the Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted cash</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash is defined as cash held for a specific purpose and not available for immediate general business use. It is classified as a current or non-current asset based on the expected timing of release. All restricted cash is included in the unaudited condensed consolidated statement of cash flows as part of total cash and cash equivalents. Liquidity ratios exclude restricted cash to reflect actual liquidity. Restrictions are documented and reviewed quarterly. Restricted cash consists of funds held in escrow accounts and cash collateral required under certain loan agreements as more detailed in Note 7.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Classification of Preferred Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies the guidance of ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”), when determining the classification and measurement of its preferred stock. Preferred stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies contingently redeemable preferred stock (if any), which includes preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity. At all other times, the Company classifies its preferred stock in stockholders’ equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Embedded Derivatives</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews the terms of convertible loan notes and other hybrid financing arrangements to determine whether there are embedded derivative instruments, including conversion options that are required to be bifurcated and accounted for separately either as a derivative financial instrument or an equity instrument. Derivatives are accounted for under ASC 815, <i>Derivatives and Hedging</i>. Derivative financial instruments are initially measured at fair value, and then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations as a component of net income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The discount from face value of the liability component remaining from allocating some or all of the proceeds of the hybrid instrument to the derivative, together with the stated rate of interest on the instrument, is amortized over the life of the instrument through periodic charges to consolidated statements of operations, using the effective interest method. <i>Embedded derivatives</i> that are bifurcated and recognized as liability instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Note A-1 contains a limited redemption feature to redeem Note A-1 principal on any trading day on which the Company’s common stock trades at or above 115% of the Nasdaq Minimum Price, in an amount up to 5% of the cumulative daily dollar trading volume in aggregate across the outstanding Notes. The Company determined that this feature is not clearly and closely related to the promissory notes host and meets the definition of a derivative. The feature has been bifurcated and is recorded as a derivative liability measured at fair value. (For further details, see “Note 7. Preferred Stock and Notes Payable”)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Debt Issuance Costs and Discount</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt issuance costs include incremental and direct costs incurred in relation to debt, such as legal fees, accounting fees, and other direct costs of the financing. Amounts paid to the lender are a reduction in the proceeds received by the Company and are generally considered a component of issuance discount, unless it is paid to compensate the lender for the services rendered or as a reimbursement of direct costs incurred by them in relation to the debt, in which case it would be akin to a debt issuance cost.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt issuance costs related to a recognized promissory note liability are presented in the consolidated balance sheets as a direct deduction from the carrying amount of the debt liability rather than as an asset, consistent with the presentation of debt discounts, and are amortized to interest expense over the term of the related debt using the effective interest method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred Stock Issuance Costs</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred stock issuance costs consist of specific incremental costs directly attributable to the issuance of preferred stock. These include placement agent and broker fees, legal and accounting fees (including comfort letter fees), and other direct costs of the offering. In accordance with SEC Staff Accounting Bulletin (“SAB”) Topic 5.A, Expenses of Offering, these costs are charged against the gross proceeds of the offering. When preferred stock is issued together with other financial instruments in a single transaction, issuance costs are allocated among the instruments issued based on their relative values. The portion allocated to debt instruments is accounted for as described under “Debt Issuance Costs and Discount.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern Uncertainty</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company’s research and development programs, clinical trials conducted in connection with the Company’s drug candidates, and applications and submissions to the FDA. The Company has not generated significant revenue and has incurred significant net losses in each year since inception. For the nine months ended September 30, 2026, the Company had a net loss of $<span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20260101__20260930_zwl6kYBlFtQd" title="Net loss">10.8</span> million and used $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20260101__20260930_zCAqFmT0Et2a" title="Cash to fund operation">10.2</span> million to fund operations. As of September 30, 2026, the Company incurred approximately $<span id="xdx_90C_ecustom--CumulativeNetIncomeLoss_iI_pn5n6_c20260930_zfJ0POmKSVs" title="Cumulative net loss">432.1</span> million of cumulative net losses and had $<span id="xdx_90C_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20260930_zKGS59h8OKi5" title="Cash and cash equivalents, short-term investments, and interest receivable">4.0</span> million in cash and cash equivalents to fund its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U.S. and worldwide resulting from the tariffs announcement by the U.S. federal government, the Russian invasion of Ukraine and the unrest in the Middle East and in Europe. The Company continues to monitor its operating activities in light of these events, and it is possible that these events could result in a variety of risks to the business. The specific impact, if any, is not readily determinable as of the date of these unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has based its estimates on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company’s shares or debt and other sources. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of existing stockholders may be diluted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company’s control. These factors include the progress of research activities; the progress of preclinical and clinical development activities; the progress of the development efforts of parties with whom the Company has entered into research and development agreements; the costs associated with additional clinical trials of drug candidates; the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements; the ability to achieve milestones under licensing arrangements; the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and the costs and timing of regulatory approvals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A fundamental component of the ability to continue as a going concern is the Company’s ability to raise capital as required, as to which no assurances can be provided. To address the additional funding requirements of the Company, management has undertaken the following initiatives:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it continues to address its current expenditures and will reduce spending where necessary;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it continues to pursue additional capital funding in the public and private markets through equity sales and/or debt facilities;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it continues to pursue partnerships and collaborations; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it continues to pursue out licensing for its drug candidates and/or platform technology.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s ability to continue as a going concern will depend on its ability to raise additional capital, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue. There are no assurances that these future funding and operating efforts will be successful. If management is unsuccessful in these efforts, the Company’s current capital is not expected to be sufficient to fund operations for the next twelve months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern. The report of our independent registered public accounting firm for the year ended December 31, 2025, includes an explanatory paragraph which expresses substantial doubt about our ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management’s plan includes private or public equity and debt financings, collaborations, and/or partnerships, or other strategic transactions such as raising funds from investors through its ATM program and the proposed public offering filed on Form S-1, as further described in Note 13. The Company may not be able to obtain funding on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control, and it may be unable to raise financing when needed, or on terms favorable to the Company. If the Company is unable to obtain sufficient capital to fund its operations it may be required to evaluate alternatives. The Company’s unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -10800000 -10200000 432100000 4000000.0 <p id="xdx_805_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zI1tDsxViNXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3. <span id="xdx_82B_zXOKQWql6OA2">New Accounting Pronouncements </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s consolidated financial position, results of operations, and cash flows, or does not apply to its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as “Cost of sales” and “Selling, general and administrative expenses”. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact, if any, this change will have on the Company’s disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2025, the FASB issued ASU 2025-11, “Narrow Scope Improvements” (“ASU 2025-11”) which is intended to improve the navigability of the guidance in Interim Reporting (Topic 270) and clarify when it applies. Under the amendments, an entity is subject to ASC 270 if it provides “interim financial statements and notes in accordance with GAAP.” ASU 2025-11 also addresses the form and content of such financial statements, adds lists to ASC 270 of the interim disclosures required by all other codification topics, and establishes a principle under which an entity must “disclose events since the end of the last annual reporting period that have a material impact on the entity.” As the FASB stated in the proposed guidance and reiterates in 2025-11, the amendments are not intended to “change the fundamental nature of interim reporting or expand or reduce current interim disclosure requirements”. ASU 2025-11 is effective for interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company does not believe ASU 2025-11 will have a material effect on its unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that the Company believes have a material impact, or potential material impact, to its unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_807_eus-gaap--EarningsPerShareTextBlock_zfP8j2Xgrfo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4. <span id="xdx_82F_zcuVyaOvxccg">Net Loss per Common Share Available to Common Shareholders</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per common share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the period. Net loss available to common shareholders is net loss less the preferred return accumulated during the period on the Series A Preferred Stock and Series B Preferred Stock, whether or not declared, in accordance with ASC 260-10-45-11. See Note 7 for the terms of the Series A Preferred Stock and Series B Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted net loss per common share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the period, plus the dilutive effect, if any, of potential common shares. Potential common shares consist of shares issuable upon the exercise of outstanding common stock warrants and stock options, determined using the treasury stock method. The Company reported a net loss available to common shareholders for all periods presented. Including potential common shares would therefore have been anti-dilutive, so diluted net loss per common share is the same as basic net loss per common share for all periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As more fully described in Note 8 of unaudited condensed consolidated financial statements, on December 31, 2025, the Company completed the sale of a security offering that included prefunded warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zqjp5MOqdjGh" title="Warrants outstanding">1,609,114</span> shares of the Company’s common stock for $<span id="xdx_900_eus-gaap--SharePrice_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z9Zg1jMb5lka" title="Share price">0.01</span> per share of which none remained outstanding as of September 30, 2026. In accordance with ASC 260-10-45-13, these pre-funded warrants, sometimes referred to as penny stock warrants due to their low exercise price ($<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260930__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zwxQKhADcpIk" title="Warrant exercise price">0.0001</span>/share), are considered outstanding shares for purposes of calculating earnings per share for the three months and nine months ended September 30, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series A Preferred Stock and Series B Preferred Stock are not convertible into common stock and therefore do not represent potential common shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As more fully described in Note 8 of these unaudited condensed consolidated financial statements, the Company declared a <span id="xdx_900_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250807__20250807_zJxfxiQtUnz5" title="Stock dividend percentage">15</span>% stock dividend that was distributed on August 21, 2025 to stockholders of record as of August 7, 2025. In accordance with ASC 260, basic and diluted earnings per share amounts and weighted-average shares outstanding have been restated for all periods in 2025 presented to reflect the effect of this stock dividend. The Company did not pay any dividends during the first nine months of 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNcMTBAPnb4a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the computation of basic and diluted net loss per common share:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B0_zCZvLgM8XH6b" style="display: none">Schedule of Computation of Basic and Diluted Net Loss per Common Share</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20260701__20260930_z6zWw67ubOAa" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20250701__20250930_zv0VrtXjLkYg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49A_20260101__20260930_zwhuJthauIJ4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_496_20250101__20250930_zJA3cbiWHmkc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Three Months Ended <br/>September 30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Nine Months Ended <br/> September 30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zeC5H50sOWve" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss available to common share available to common shareholders</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,813,418</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,429,124</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,894,606</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,272,178</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per common share available to common shareholders</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_i01_pid_c20260701__20260930_zv9L5xJJx9x4" title="Net loss per common share available to common shareholders Basic"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_i01_pid_c20260701__20260930_zIbw3Jeu0nq4" title="Net loss per common share available to common shareholders Diluted">(0.64</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_i01_pid_c20250701__20250930_zEIvfzlsO69g" title="Net loss per common share available to common shareholders Basic"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_i01_pid_c20250701__20250930_zM4TjP4z5Oif" title="Net loss per common share available to common shareholders Diluted">(1.16</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_i01_pid_c20260101__20260930_zd6lZHYVd3qh" title="Net loss per common share available to common shareholders Basic"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_i01_pid_c20260101__20260930_zRHxfO7Pz76e" title="Net loss per common share available to common shareholders Diluted">(2.01</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_i01_pid_c20250101__20250930_zr94Zt7XpVjd" title="Net loss per common share available to common shareholders Basic"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_i01_pid_c20250101__20250930_z3L1WpLpbnX8" title="Net loss per common share available to common shareholders Diluted">(5.53</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average shares outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_c20260701__20260930_zGi6qBE6s6lb" title="Weighted average shares outstanding Basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_c20260701__20260930_z1G6gy4AOAA1" title="Weighted average shares outstanding Diluted">5,947,263</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_c20250701__20250930_z6iBZaWjYeqg" title="Weighted average shares outstanding Basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_c20250701__20250930_zL4XRZx5cN3j" title="Weighted average shares outstanding Diluted">2,943,655</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_c20260101__20260930_zhCc0uh2uPjd" title="Weighted average shares outstanding Basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_c20260101__20260930_zbdre4h0xJHd" title="Weighted average shares outstanding Diluted">5,408,092</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_c20250101__20250930_zMuCnD9NApI5" title="Weighted average shares outstanding Basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_c20250101__20250930_zpdiWSBeUbK7" title="Weighted average shares outstanding Diluted">1,855,922</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AB_zR5yZLTcLrn" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zpey3CKoiK6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following potentially dilutive securities, presented as of the end of each period, were excluded from the computation of diluted net loss per common share because their effect would have been anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_ztVcO6QoKqLc" style="display: none">Schedule of Computation of Diluted Net Loss per Common Share Anti-dilutive Securities </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260101__20260930_zN0wK7pHiEuf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250101__20250930_zsvXzImrrkd9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z45oc1XHTU18" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Common stock warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">2,904,361</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">965,247</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zI97rwyR6Gyj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Stock options</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">258,646</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">24,986</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zFXLZuQsg1h1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,163,007</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">990,233</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zvPT3GR22pg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1609114 0.01 0.0001 0.15 <p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNcMTBAPnb4a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the computation of basic and diluted net loss per common share:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B0_zCZvLgM8XH6b" style="display: none">Schedule of Computation of Basic and Diluted Net Loss per Common Share</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20260701__20260930_z6zWw67ubOAa" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20250701__20250930_zv0VrtXjLkYg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49A_20260101__20260930_zwhuJthauIJ4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_496_20250101__20250930_zJA3cbiWHmkc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Three Months Ended <br/>September 30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Nine Months Ended <br/> September 30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zeC5H50sOWve" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss available to common share available to common shareholders</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,813,418</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,429,124</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,894,606</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,272,178</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per common share available to common shareholders</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_i01_pid_c20260701__20260930_zv9L5xJJx9x4" title="Net loss per common share available to common shareholders Basic"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_i01_pid_c20260701__20260930_zIbw3Jeu0nq4" title="Net loss per common share available to common shareholders Diluted">(0.64</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_i01_pid_c20250701__20250930_zEIvfzlsO69g" title="Net loss per common share available to common shareholders Basic"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_i01_pid_c20250701__20250930_zM4TjP4z5Oif" title="Net loss per common share available to common shareholders Diluted">(1.16</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_i01_pid_c20260101__20260930_zd6lZHYVd3qh" title="Net loss per common share available to common shareholders Basic"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_i01_pid_c20260101__20260930_zRHxfO7Pz76e" title="Net loss per common share available to common shareholders Diluted">(2.01</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_i01_pid_c20250101__20250930_zr94Zt7XpVjd" title="Net loss per common share available to common shareholders Basic"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_i01_pid_c20250101__20250930_z3L1WpLpbnX8" title="Net loss per common share available to common shareholders Diluted">(5.53</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average shares outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_c20260701__20260930_zGi6qBE6s6lb" title="Weighted average shares outstanding Basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_c20260701__20260930_z1G6gy4AOAA1" title="Weighted average shares outstanding Diluted">5,947,263</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_c20250701__20250930_z6iBZaWjYeqg" title="Weighted average shares outstanding Basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_c20250701__20250930_zL4XRZx5cN3j" title="Weighted average shares outstanding Diluted">2,943,655</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_c20260101__20260930_zhCc0uh2uPjd" title="Weighted average shares outstanding Basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_c20260101__20260930_zbdre4h0xJHd" title="Weighted average shares outstanding Diluted">5,408,092</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_c20250101__20250930_zMuCnD9NApI5" title="Weighted average shares outstanding Basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_c20250101__20250930_zpdiWSBeUbK7" title="Weighted average shares outstanding Diluted">1,855,922</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> -3813418 -3429124 -10894606 -10272178 -0.64 -0.64 -1.16 -1.16 -2.01 -2.01 -5.53 -5.53 5947263 5947263 2943655 2943655 5408092 5408092 1855922 1855922 <p id="xdx_893_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zpey3CKoiK6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following potentially dilutive securities, presented as of the end of each period, were excluded from the computation of diluted net loss per common share because their effect would have been anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_ztVcO6QoKqLc" style="display: none">Schedule of Computation of Diluted Net Loss per Common Share Anti-dilutive Securities </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260101__20260930_zN0wK7pHiEuf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250101__20250930_zsvXzImrrkd9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z45oc1XHTU18" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Common stock warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">2,904,361</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">965,247</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zI97rwyR6Gyj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Stock options</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">258,646</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">24,986</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zFXLZuQsg1h1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,163,007</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">990,233</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 2904361 965247 258646 24986 3163007 990233 <p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zFE5LCUrDBAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5. <span id="xdx_82F_zGTam0ldMlBc">Segment Performance Measures and Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in <span id="xdx_902_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20260101__20260930_z6cenMGtEjM9" title="Number of operating segment">one</span> segment for the research and development of our product candidates. The Company’s chief operating decision maker (“CODM”) has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company based on consolidated financial information. Consequently, we view the entire organization as <span id="xdx_903_eus-gaap--NumberOfReportableSegments_pid_dc_uSegment_c20260101__20260930_zBIJVQG2X5y9" title="Number of reportable segment">one</span> reportable segment and the strategic purpose of all operating activities (including general and administrative expenses) is to support that one segment. As a pre-revenue research and development company, the CODM evaluates company-wide performance and allocates resources based on non-financial research and development milestones achieved, and to a lesser extent, financial measures of performance such as clinical development (research and development expenses) and general and administrative expenses incurred. Our CODM does not generally evaluate our performance using asset or historical cash flow information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zTLk2XZYS2Mj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zr58bMnj4ja4" style="display: none">Schedule of Significant Expense Categories and Consolidated Net Loss</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zN6sMi8ywXj7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zUVWJ6ukX17j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change Increase (Decrease)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating Expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Clinical Research</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OvationTrialsMember_zHJhaRbKXSue" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left; padding-left: 20pt">OVATION Trials (Phase 2 &amp; 3)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">774</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">800</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OvationTrialsMember_zeF3uqTPS9h2" style="width: 10%; text-align: right" title="Change Increase (Decrease), Subtotal">(26</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OvationTrialsMember_zZ8RtX6KjfGa" style="width: 10%; text-align: right" title="Change Increase (Decrease), Subtotal, percentage">-3</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_400_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--MRDStudyMember_z0gkusaISdt5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 20pt">MRD Study</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--MRDStudyMember_z2pcsllFfdch" style="text-align: right" title="Change Increase (Decrease), Subtotal">63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--MRDStudyMember_zhVvHdPSZLLa" style="text-align: right" title="Change Increase (Decrease), Subtotal, percentage">59</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember_z0XCnPmzB9jl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 20pt">PlaCCine Vaccine Phase 1 Trial</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember_zhjzaNoYppsc" style="text-align: right" title="Change Increase (Decrease), Subtotal">(42</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember_zCXfizOSXpA5" style="text-align: right" title="Change Increase (Decrease), Subtotal, percentage">-100</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OtherClinicalAndRegulatoryMember_zDz21sw3cDZb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Other Clinical and Regulatory</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,379</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,387</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OtherClinicalAndRegulatoryMember_z2J3a2nNfJvb" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal">(8</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OtherClinicalAndRegulatoryMember_zoWZDj8YGBp2" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal, percentage">-1</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember_ztLWqO08hBLd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 30pt">Subtotal</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,322</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,335</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember_zNxwFClBmMSc" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal">(13</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember_zRmpzcjO2M8g" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal, percentage">-1</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Non-Clinical R&amp;D and CMC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__us-gaap--SubsegmentsAxis__custom--ManufacturingAndClinicalSupplyMember_zbxhXRHaEfF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 30pt">Manufacturing &amp; Clinical Supply</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,272</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,955</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__us-gaap--SubsegmentsAxis__custom--ManufacturingAndClinicalSupplyMember_zxf8QObA4gL5" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal">317</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__us-gaap--SubsegmentsAxis__custom--ManufacturingAndClinicalSupplyMember_z0d5G6IlFJmd" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal, percentage">11</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember_zAWQLHtjgXJf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Subtotal</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,272</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,955</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember_z0ihCDsOm2Nh" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal">317</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember_zh4Oil4xips6" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal, percentage">11</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_maOEzKYj_zWiatSO3UWQh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,594</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--IncreaseDecreaseInResearchAndDevelopmentExpense_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zI0fayeKwdRi" style="text-align: right" title="Change Increase (Decrease), Research and development expenses">304</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--IncreaseDecreaseInResearchAndDevelopmentExpensesPercentage_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zyooTUcMqJSg" title="Change Increase (Decrease), Research and development expenses, percentage">6</span></td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_maOEzKYj_zmf31Juf8HR5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,951</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,098</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--IncreaseDecreaseInGeneralAndAdministrativeExpenes_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zfi7WCMELsFk" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), General and administrative expenses">(147</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_ecustom--IncreaseDecreaseInGeneralAndAdministrativeExpensesPercentage_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zmfaKeXBaS76" title="Change Increase (Decrease), General and administrative expenses, percentage">-3</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--OperatingExpenses_iT_pn3n3_mtOEzKYj_msOILzHN5_z5KIM1M8DzId" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,545</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,388</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--IncreaseDecreaseInOperatingExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zNnscj0mfSof" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Operating expenses">157</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--IncreaseDecreaseInOperatingExpensesPercentage_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zJRtpgZLDcDd" title="Change Increase (Decrease), Operating expenses, percentage">2</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_iNT_pn3n3_di_mtOILzHN5_zjBBXk3e6206" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,545</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,388</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--IncreaseDecreaseInLossFromOperations_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zmga2nM1iBYd" style="border-bottom: Black 2.5pt double; text-align: right" title="Change Increase (Decrease), Loss from operations">157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--IncreaseDecreaseInLossFromOperationsPercentage_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zxQGZAarUMsb" title="Change Increase (Decrease), Loss from operations, percentage">2</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8AB_zJaYrTXRKLK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 1 1 <p id="xdx_89A_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zTLk2XZYS2Mj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zr58bMnj4ja4" style="display: none">Schedule of Significant Expense Categories and Consolidated Net Loss</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zN6sMi8ywXj7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zUVWJ6ukX17j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change Increase (Decrease)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating Expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Clinical Research</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OvationTrialsMember_zHJhaRbKXSue" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left; padding-left: 20pt">OVATION Trials (Phase 2 &amp; 3)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">774</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">800</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OvationTrialsMember_zeF3uqTPS9h2" style="width: 10%; text-align: right" title="Change Increase (Decrease), Subtotal">(26</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OvationTrialsMember_zZ8RtX6KjfGa" style="width: 10%; text-align: right" title="Change Increase (Decrease), Subtotal, percentage">-3</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_400_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--MRDStudyMember_z0gkusaISdt5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 20pt">MRD Study</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--MRDStudyMember_z2pcsllFfdch" style="text-align: right" title="Change Increase (Decrease), Subtotal">63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--MRDStudyMember_zhVvHdPSZLLa" style="text-align: right" title="Change Increase (Decrease), Subtotal, percentage">59</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember_z0XCnPmzB9jl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 20pt">PlaCCine Vaccine Phase 1 Trial</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember_zhjzaNoYppsc" style="text-align: right" title="Change Increase (Decrease), Subtotal">(42</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember_zCXfizOSXpA5" style="text-align: right" title="Change Increase (Decrease), Subtotal, percentage">-100</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OtherClinicalAndRegulatoryMember_zDz21sw3cDZb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Other Clinical and Regulatory</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,379</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,387</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OtherClinicalAndRegulatoryMember_z2J3a2nNfJvb" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal">(8</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OtherClinicalAndRegulatoryMember_zoWZDj8YGBp2" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal, percentage">-1</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember_ztLWqO08hBLd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 30pt">Subtotal</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,322</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,335</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember_zNxwFClBmMSc" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal">(13</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember_zRmpzcjO2M8g" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal, percentage">-1</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Non-Clinical R&amp;D and CMC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__us-gaap--SubsegmentsAxis__custom--ManufacturingAndClinicalSupplyMember_zbxhXRHaEfF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 30pt">Manufacturing &amp; Clinical Supply</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,272</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,955</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__us-gaap--SubsegmentsAxis__custom--ManufacturingAndClinicalSupplyMember_zxf8QObA4gL5" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal">317</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__us-gaap--SubsegmentsAxis__custom--ManufacturingAndClinicalSupplyMember_z0d5G6IlFJmd" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal, percentage">11</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember_zAWQLHtjgXJf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Subtotal</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,272</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,955</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember_z0ihCDsOm2Nh" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal">317</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember_zh4Oil4xips6" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal, percentage">11</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_maOEzKYj_zWiatSO3UWQh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,594</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--IncreaseDecreaseInResearchAndDevelopmentExpense_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zI0fayeKwdRi" style="text-align: right" title="Change Increase (Decrease), Research and development expenses">304</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--IncreaseDecreaseInResearchAndDevelopmentExpensesPercentage_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zyooTUcMqJSg" title="Change Increase (Decrease), Research and development expenses, percentage">6</span></td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_maOEzKYj_zmf31Juf8HR5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,951</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,098</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--IncreaseDecreaseInGeneralAndAdministrativeExpenes_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zfi7WCMELsFk" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), General and administrative expenses">(147</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_ecustom--IncreaseDecreaseInGeneralAndAdministrativeExpensesPercentage_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zmfaKeXBaS76" title="Change Increase (Decrease), General and administrative expenses, percentage">-3</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--OperatingExpenses_iT_pn3n3_mtOEzKYj_msOILzHN5_z5KIM1M8DzId" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,545</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,388</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--IncreaseDecreaseInOperatingExpenses_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zNnscj0mfSof" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Operating expenses">157</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--IncreaseDecreaseInOperatingExpensesPercentage_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zJRtpgZLDcDd" title="Change Increase (Decrease), Operating expenses, percentage">2</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_iNT_pn3n3_di_mtOILzHN5_zjBBXk3e6206" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,545</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,388</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--IncreaseDecreaseInLossFromOperations_pn3n3_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zmga2nM1iBYd" style="border-bottom: Black 2.5pt double; text-align: right" title="Change Increase (Decrease), Loss from operations">157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--IncreaseDecreaseInLossFromOperationsPercentage_dp_uPure_c20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zxQGZAarUMsb" title="Change Increase (Decrease), Loss from operations, percentage">2</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> 774000 800000 -26000 -0.03 169000 106000 63000 0.59 42000 -42000 -1 1379000 1387000 -8000 -0.01 2322000 2335000 -13000 -0.01 3272000 2955000 317000 0.11 3272000 2955000 317000 0.11 5594000 5290000 304000 0.06 4951000 5098000 -147000 -0.03 10545000 10388000 157000 0.02 -10545000 -10388000 157000 0.02 <p id="xdx_807_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z8Z7E634bsm5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6. <span id="xdx_82B_z3qVWYq14tJ1">Other Accrued Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z8aAXo9dBtTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other accrued liabilities at September 30, 2026 and December 31, 2025 include the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zYwl5b9pk3c7" style="display: none">Schedule of Other Accrued Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20260930_z0S4y9Qq2QBh" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_492_20251231_zZLahetRQAm5" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--ContractualObligation_iI_maCz80K_zLAZwwQNbVji" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Amounts due to contract research organizations and other contractual agreements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">573,970</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,001,210</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maCz80K_zD7nOUVH4IOf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued payroll and related benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">314,286</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,611,936</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maCz80K_zdovBm2hbmn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accrued professional fees, interest expense, franchise taxes and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">249,090</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">211,500</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtCz80K_z6sYx4kI103g" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,137,346</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,824,646</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zcQn6TjpQIGf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z8aAXo9dBtTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other accrued liabilities at September 30, 2026 and December 31, 2025 include the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zYwl5b9pk3c7" style="display: none">Schedule of Other Accrued Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20260930_z0S4y9Qq2QBh" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_492_20251231_zZLahetRQAm5" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--ContractualObligation_iI_maCz80K_zLAZwwQNbVji" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Amounts due to contract research organizations and other contractual agreements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">573,970</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,001,210</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maCz80K_zD7nOUVH4IOf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued payroll and related benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">314,286</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,611,936</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maCz80K_zdovBm2hbmn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accrued professional fees, interest expense, franchise taxes and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">249,090</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">211,500</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtCz80K_z6sYx4kI103g" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,137,346</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,824,646</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 573970 1001210 314286 1611936 249090 211500 1137346 2824646 <p id="xdx_804_ecustom--PreferredStockAndNotesPayableDisclosureTextBlock_zLaJy2Tvarmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7. <span id="xdx_822_zeG4SqWZ6il1">Preferred Stock and Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_890_eus-gaap--ScheduleOfDebtTableTextBlock_zlwxH5K5VeD7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt consists of following as of September 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zorSdCF4aOL1" style="display: none">Schedule of Debt</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260930_zZPpOyThfkof" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--NoteAOneMember_zV92ha6YZAMi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 80%">Note A-1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,590,166</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--NoteBMember_zHEfAZKRsVH4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Note B</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,000,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DebtInstrumentCarryingAmount_iI_zc0btE5awyxj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total Debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,590,166</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NotesPayableCurrent_iNI_di_zFqUx96y3WH8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: current portion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,344,728</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_zt9ao1Z1Bibl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: unamortized debt discount and issuance costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(360,813</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--LongTermNotesPayable_iI_zDJ2lhzqjD72" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Debt, net of discount and issuance costs</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,884,625</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_z63L10aeDrp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 2, 2026, the Company entered into a Securities Purchase Agreement (the “June 2026 Securities Purchase Agreement”) with Streeterville Capital, LLC (the “Investor”), providing for the issuance and sale by the Company, and the purchase by the Investor, of (i) <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260602__20260602__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTy8nmJgDlA4" title="Number of shares issued">250</span> shares (the “Preferred Shares”) of the Company’s Series A Preferred Stock, par value $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260602__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zReTY1zlZAWd" title="Preferred stock, per share">0.01</span> per share (the “Series A Preferred Stock”), at an issued value of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20260602__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_za8CcCIjB7xb" title="Preferred stock, issued value per share">10,000</span> per share and a stated value of $<span id="xdx_900_ecustom--PreferredStockStatedValuePerShare_iI_c20260602__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCRs5WLodexi" title="Preferred stock, stated value per share">12,000</span> per share, for aggregate gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20260602__20260602__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyP7NZuxHYMi" title="Gross proceeds">2,500,000</span>; (ii) a Secured Promissory Note A-1 in an original principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20260602__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember_z0a0xKKPhP9k" title="Note principal amount">2,720,000</span> (the “Note A-1”); and (iii) a Secured Promissory Note B in an original principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20260602__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteBMember_zGfRmcJkRSKe" title="Note principal amount">5,000,000</span> (the “Note B” and together with the Note A-1, the “Notes”). The transactions contemplated by the Securities Purchase Agreement (collectively, the “Transaction”) closed on June 3, 2026 (the “Closing Date”). At closing, the Company received $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20260603__20260603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zLJwpIkzQei6" title="Amount received from investor">10,000,000</span> from the Investor, $<span id="xdx_90B_eus-gaap--PaymentsForDeposits_c20260603__20260603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zlLeBa3RpoQj" title="Amount deposited into bank">5,000,000</span> of which was deposited into a bank account owned by a wholly owned subsidiaries of the Company as cash collateral for the Notes (the “Cash Collateral Account”). The $<span id="xdx_907_eus-gaap--RestrictedCash_iI_c20260603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_z7NMrSsScQud" title="Restricted cash">5,000,000</span> amount is classified as restricted cash on the condensed consolidated balance sheet. The obligations under the Notes are secured by substantially all of the assets of the Company, other than its intellectual property assets, and are guaranteed by certain of the Company’s subsidiaries. The Company intends to utilize the $<span id="xdx_906_eus-gaap--PaymentsForOperatingActivities_c20260603__20260603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_z2ENV9TdAez2" title="Proceeds used for general corporate purposes">5,000,000</span> of proceeds from the closing of the Transaction, along with any proceeds later released from the Cash Collateral Account, for general corporate purposes, including research and development activities, capital expenditures and working capital. The Company agreed to pay the placement agents for financing a fee of <span id="xdx_908_ecustom--FinancingFeePercentage_pid_dp_c20260603__20260603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_z1FzxPg3QBs2" title="Financing fee percentage">7.0</span>% of the gross proceeds received by the Company in connection with the Transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DebtConversionDescription_c20260603__20260603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zsYb0gRNzkZ" title="Description of note conversion">If the aggregate outstanding balance of the Note A-1 or the aggregate number of outstanding Preferred Shares is reduced by $2,000,000, the Company will have the right to exchange up to $1,000,000, plus interest (or, if less than $1,000,000, the entire remaining amount of the Note B, or such other amount as the parties mutually agree), of the Note B for a new secured note in the same form and having the same terms as the Note A-1 (each, a “Note Exchange”). Upon the completion of each Note Exchange, an amount of cash equal to the amount of the Note B exchanged in such Note Exchange will be released from the Cash Collateral Account to the Company. The Note A-1 will accrue payment-in-kind (PIK) interest at a rate of 8% per annum, which will be added to the outstanding principal balance of the Note A-1, and will mature 18 months following the Closing Date.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Note B will bear interest at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20260603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteBMember_zhDPBVuxG97j" title="Note interest rate">5</span>% per annum and will mature 18 months following the Closing Date. <span id="xdx_90B_eus-gaap--DebtInstrumentRedemptionDescription_c20260603__20260603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_z5IkfrSZu5I" title="Description of note redemption">The Notes can be prepaid by the Company in whole or in part at any time, subject to a 10% prepayment premium on any principal amounts prepaid. Beginning six months after the Closing Date, the Investor may redeem up to $250,000 of the principal amount of the Note A-1 each calendar month. In addition, on any trading day when the Company’s common stock trades at a price that is at least 15% greater than the “Minimum Price” as defined under Nasdaq Stock Market LLC Rule 5635(d), the Investor may redeem an additional principal amount of the Notes equal to 5% of the trading volume of the Company’s common stock on such trading day.</span> The Company will be subject to customary covenants while the Notes remain outstanding. <span id="xdx_902_eus-gaap--DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_c20260603__20260603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zxpo0wYYX0Gd" title="Description of note default">The Notes also contain customary events of default, the occurrence of which would permit the Investor to accelerate the obligations under the Notes and exercise remedies against any collateral (including amounts on deposit in the Cash Collateral Account) or guarantees in respect of the Notes. In addition, following the occurrence of an event of default, the interest rate of each Note would increase to the lesser of 15% per year or the maximum rate permitted by applicable law.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker fees totaling $<span id="xdx_90D_eus-gaap--PaymentsForBrokerageFees_c20260603__20260603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zYNaFlw3cTX4" title="Broker fees">350,000</span> were allocated between the preferred stock and Note A-1 based on their values. Issuance costs, which primarily include legal fees totaling $<span id="xdx_903_eus-gaap--LegalFees_c20260603__20260603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_z7mQJ3nRILxg" title="Legal fees">292,310</span>, were allocated between the preferred stock and Note A-1 and Note B based on the face value of each financial instrument and will be amortized over the life of the instruments. The original issuance discount associated with Note A-1 was recorded as a contra-liability to be amortized over the life of the note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--InterestIncomeAndInterestExpenseDisclosureTableTextBlock_zL8JOC7IOFkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense consistent of following for nine months ended September 30:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zNrHvKYpNkG4" style="display: none">Schedule of Interest Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260701__20260930_zaO3n6WmfT0i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250701__20250930_zL6IvyuFHaE3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260101__20260930_zoQikwAJDBff" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250101__20250930_zGpHUn6X9Op" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended <br/>September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended <br/>September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--InterestExpenseDebt_hus-gaap--LongtermDebtTypeAxis__custom--NoteAOneMember_zMW9cIaq9aua" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Interest expense on Note A-1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">54,070</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">70,166</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InterestExpenseDebt_hus-gaap--LongtermDebtTypeAxis__custom--NoteBMember_zpwML8FSOvEg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest expense on Note B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64,005</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82,789</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_hus-gaap--LongtermDebtTypeAxis__custom--NoteAOneMember_zOHcLuJwnpCc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortization of debt discount and issuance costs on Note A-1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">122,264</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157,674</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AmortizationOfFinancingCosts_hus-gaap--LongtermDebtTypeAxis__custom--NoteBMember_zg95qe4Hhwi4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Amortization of debt issuance costs - Note B</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">23,794</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30,777</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InterestExpenseNonoperating_z7mx22SHUWT7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">264,133</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">341,406</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_ze2QvtkHNA9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Permanent Equity Classification</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company classified the <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_c20260602__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkIaafYvOjL5" title="Preferred stock, shares issued">250</span> shares of Series A Preferred Stock as permanent stockholders’ equity as of the Closing Date. Under ASC 480-10-S99-3A, an equity instrument must be classified outside of permanent equity if it is redeemable upon the occurrence of an event not solely within the control of the issuer. On July 29, 2026, the Company and the Investor executed an Irrevocable Waiver and Covenant Not to Exercise Redemption Rights (the “Waiver”), effective as of June 2, 2026, under which the Investor irrevocably waived the default redemption right under Section 12(b)(i) of the Certificate of Designation with respect to all events of default. The Waiver is a Type 1 recognized subsequent event under ASC 855-10-25-1 that provides evidence of conditions existing at the June 3, 2026 closing date and confirms the permanent-equity classification applied as of that date. Accordingly, because the Series A Preferred Stock is not redeemable upon an event outside the Company’s control, it is classified as permanent stockholders’ equity in accordance with ASC 480-10-S99-3A.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Series A Preferred Stock accrues a preferred return at a rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSMhmha6wv28" title="Interest rate stated percentage">8</span>% per annum on its stated value, compounded daily. The preferred return is payable quarterly, either in cash or, at the Company’s election, through the issuance of additional shares of Series A Preferred Stock. The number of additional shares is determined by dividing the accrued and unpaid preferred return by the $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20260930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zstBLEdwSYsg" title="Purchase price per share">10,000</span> per-share purchase price. Fractional shares are not issued, and the portion of the preferred return that otherwise would result in the issuance of a fractional  share is payable in cash.</p> <p style="font: 10pt/15pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In the event of a voluntary or involuntary liquidation, dissolution or winding up of the Company, each outstanding share of Series A Preferred Stock is entitled to receive, before any distribution to holders of common stock, an amount equal to its stated value plus any accrued and unpaid preferred return. After payment of this liquidation preference, the holders of Series A Preferred Stock do not participate in any remaining distributions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted Cash</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At September 30, 2026, approximately $<span id="xdx_909_eus-gaap--RestrictedCash_iI_c20260930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_z1jQ9SMwRNBe" title="Restricted cash">5.0 </span>million was held in a restricted collateral account at Lakeside Bank in the name of a wholly owned subsidiary of the Company in connection with the Note B. This amount is classified as restricted cash on the condensed consolidated balance sheet and is included in cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Note B Amendment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 14, 2026, effective as of June 2, 2026, the Company and the Investor amended the Note B to remove its limited redemption feature - the feature permitting the Investor to redeem principal based on the trading volume of the Company’s common stock on days the stock trades at or above 115% of the Nasdaq Minimum Price. As a result, that feature applies only to the Note A-1, and no derivative liability was recorded in connection with the Note B.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Embedded Derivative Liability Note A-1 Limited Redemption</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DebtInstrumentRedemptionDescription_c20260603__20260603__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--StreetervilleCapitalLLCMember_zYDs6UmRmPxe" title="Description of note redemption">The Note A-1 contains a limited redemption feature that permits the Investor, beginning six months after closing, to redeem Note A-1 principal on any trading day on which the Company’s common stock trades at or above 115% of the Nasdaq Minimum Price, in an amount up to 5% of the cumulative daily dollar trading volume in aggregate across the outstanding Notes.</span> The Company determined that this feature is not clearly and closely related to the debt host and meets the definition of a derivative. The feature has been bifurcated and is recorded as a derivative liability measured at fair value, with changes in fair value recognized in the condensed consolidated statements of operations as “Change in fair value of derivative liability.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the bifurcated derivative was $<span id="xdx_90C_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20260603_z74vADO1MXX9" title="Derivative fair value">130,156</span> at the June 3, 2026 closing date and $<span id="xdx_90A_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20260930_zn9ZmHIQn9ie" title="Derivative fair value">34,809</span> at September 30, 2026, resulting in a gain of $<span id="xdx_906_eus-gaap--DerivativeGainLossOnDerivativeNet_c20260101__20260930_zbvwe1NvJOxc" title="Gain on derivative due to change in fair value">67,866</span> and $<span id="xdx_905_eus-gaap--DerivativeGainLossOnDerivativeNet_c20260701__20260930_zBtrPisVVaN7" title="Gain on derivative due to change in fair value">45,679</span> recognized during the nine months and three months ended September 30, 2026, respectively. Fair value was determined using a Monte Carlo simulation model classified within Level 3 of the fair value hierarchy. Significant inputs at September 30, 2026 included a common stock price of $<span id="xdx_904_eus-gaap--SharePrice_iI_c20260930__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember_zPKUIE6hqeK5" title="Common stock price per share">1.38</span>, a redemption trigger price of $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20260930__20260930__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember_z6OTvz2ZaqIf" title="Redemption trigger price">2.461</span> (<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20260930__20260930__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember_z32OaZR3I4U3" title="Threshold percentage of stock price trigger">115</span>% of the $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20260930__20260930__us-gaap--AwardTypeAxis__custom--SecuredPromissoryNoteAOneMember__srt--RangeAxis__srt--MinimumMember_zgbr6ZqDKaVh" title="Redemption trigger price">2.14</span> Nasdaq Minimum Price), annualized volatility of <span id="xdx_909_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20260930__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUQ8wexBNUUb" title="Derivative Asset (Liability) Net, Measurement Input">53.46</span>%, a risk-free rate of <span id="xdx_907_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20260930__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zHpVyg0BGdje" title="Derivative measurement input">4.5</span>%, and normalized average daily trading volume of <span id="xdx_90E_eus-gaap--SharesIssued_iI_pid_c20260930__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember_zcoyCJVyhAsh" title="Average trading volume shares">68,482</span> shares. At the June 3, 2026 closing date, the corresponding inputs included a common stock price of $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20260603__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember_zJcIbXgZqirg" title="Common stock price per share">2.10</span>, annualized volatility of <span id="xdx_902_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20260603__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_z6JWnVKJ8aXe" title="Derivative measurement input">22.84</span>%, and normalized average daily trading volume of <span id="xdx_906_eus-gaap--SharesIssued_iI_pid_c20260603__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember_znjhpEw0fjFa" title="Average trading volume shares">41,177</span> shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z077e0st74Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reconciles the derivative liability for the redemption feature of the A-1 Note, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B9_z8skSTsjSHIf" style="display: none">Schedule of Fair Value on Recurring Basis Using Significant Unobservable Inputs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20260101__20260930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--NoteAOneMember_zd8kbfd0Ryh8" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--DerivativeLiabilitiesCurrent_iS_z3iTwqD5mNh4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Balance at beginning of period</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1109">–</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--InitialRecognitionUponIssuanceOfDebt_zpPK1ZLJZfU4" style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Initial recognition upon issuance of A-1 Note (June 3, 2026)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">130,156</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DerivativeGainLossOnDerivativeNet_z6iywVaVLHgi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value recognized in earnings ⁽¹⁾</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(67,866</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--DerecognitionUponPartialExtinguishment_zoY6VtZv2frc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Derecognition upon partial extinguishment of A-1 Note</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(27,481</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DerivativeLiabilitiesCurrent_iE_zhqNETS3Nppf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance at end of period</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">34,809</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zRATlqMWmsp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conversion of a Portion of the A-1 Secured Promissory Note into Series B Preferred Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 28, 2026, the Company entered into an exchange agreement with Streeterville Capital, LLC pursuant to which the Company exchanged $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20260928__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember_zz3fWSlqLfNe" title="Outstanding principal amount">1.2</span> million of the outstanding principal amount of its Secured Promissory Note A-1 (the “Note A-1”) for <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260928__20260928__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z5qiNHY9ptkk" title="Number of stock issued">120</span> newly issued shares of Series B Preferred Stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20260928__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z4ydSc8rx37d" title="Preferred stock par value">0.01</span> per share (the “Series B Preferred Stock”). The Series B Preferred Stock was issued at a conversion price of $<span id="xdx_90F_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20260928__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z56b9WLUoizj" title="Preferred stock issued at conversion price">10,000</span> per share and has a stated value of $<span id="xdx_90C_ecustom--PreferredStockStatedValue_iI_pid_c20260928__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zY7Nk72tizG" title="Preferred Stock stated value">12,000</span> per share. The transaction was undertaken, in part, to increase the Company’s stockholders’ equity in support of compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series B Preferred Stock provides for an annual preferred return of <span id="xdx_90C_ecustom--PreferredStockStatedValuePercentage_iI_pid_dp_uPure_c20260928__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zXBOKqJdCrcj" title="Preferred stock stated value percentage">8</span>% of stated value, compounded daily and payable quarterly, at the Company’s election, in cash or additional shares of Series B Preferred Stock issued at $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20260928__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zrFKEqeAPmoc" title="Shares issued price per share">10,000 </span>per share. The Series B Preferred Stock does not have voting rights, except with respect to amendments that materially and adversely affect the rights or preferences of the Series B Preferred Stock and is not convertible into common stock. Upon a liquidation, dissolution or winding up of the Company, the Series B Preferred Stock ranks pari passu with the Company’s Series A Preferred Stock and senior to the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders of the Series B Preferred Stock do not have the right to require redemption of their shares. The Company may redeem the shares, solely at the discretion of its Board of Directors, at 110% of the applicable liquidation amount, plus any accrued and unpaid preferred return. The occurrence of an event of default may increase the stated value of the Series B Preferred Stock but does not provide the holder with a right to require cash redemption. Based on these terms, the Company determined that the Series B Preferred Stock is not mandatorily redeemable and is not redeemable upon an event outside the Company’s control. Accordingly, the Series B Preferred Stock is classified within permanent stockholders’ equity under ASC 480-10-S99-3A.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The exchange was accounted for as a partial extinguishment of the Note A-1 under ASC 470-50. The Company measured the Series B Preferred Stock issued at its estimated fair value of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20260928__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember_zTXCVoqPvUnf" title="Outstanding principal amount">1.2</span> million, based on the negotiated exchange price of $<span id="xdx_90F_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20260928__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteAOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjync1iUa3Ze" title="Preferred stock issued at conversion price">10,000</span> per share. Because the Series B Preferred Stock is a newly created class of preferred stock for which no active market exists, the Company considered the negotiated, arm’s-length exchange price to be the best available evidence of fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfAmountRecognizedInConnectionWithTheExchangeTableTextBlock_zDamYLESCuf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the amounts recognized in connection with the exchange:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zsobsbKGnaK5" style="display: none">Schedule of Amounts Recognized in Connection with the Exchange</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260928__20260928_zJ6QrHOi6Alc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_ecustom--FairValueOfPreferredStockIssued_maGLOEOzk1t_zWIpbHzzVDBc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Fair value of Series B Preferred Stock issued</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,200,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--NetCarryingAmountOfDebtExtinguished_iN_di_msGLOEOzk1t_zauG61VuilPh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net carrying amount of Note A-1 extinguished</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,004,876</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--PortionOfEmbeddedDerivativeLiabilityDerecognized_iN_di_msGLOEOzk1t_zIGoz3T2UkNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Portion of embedded derivative liability derecognized</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(27,481</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_ecustom--LossOnExtinguishmentOfDebt_mtGLOEOzk1t_znmw6frRTSYi" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Loss on extinguishment of Note A-1</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">167,643</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zizy7MCphVx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net carrying amount of the Note A-1 extinguished included $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20260928__us-gaap--DebtInstrumentAxis__custom--NoteAOneMember_zJm2HhriFqH5" title="Outstanding principal amount">1.2</span> million of principal, net of approximately $<span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20260928__us-gaap--DebtInstrumentAxis__custom--NoteAOneMember_zcOj3Gz13hj4" title="Unamortized debt discount and issuance costs">202,000</span> of related unamortized debt discount and issuance costs. The Company allocated the unamortized discount and issuance costs and the embedded derivative liability between the extinguished and continuing portions of the Note A-1 based on the relative principal amounts subject to the exchange. The resulting loss on extinguishment of approximately $<span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260701__20260930__us-gaap--DebtInstrumentAxis__custom--NoteAOneMember_zAZEiJE5tyA5" title="Loss on extinguishment of debt"><span id="xdx_902_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260101__20260930__us-gaap--DebtInstrumentAxis__custom--NoteAOneMember_zu1DtwMQHgke" title="Loss on extinguishment of debt">167,643</span></span> was recognized within other income (expense) in the condensed consolidated statements of operations for the three and nine months ended September 30, 2026. Note A-1-extinguishment gains and losses are recognized currently in income and identified separately rather than deferred or amortized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately before the exchange, the Company remeasured the embedded derivative associated with the Note A-1’s limited redemption feature to its September 28, 2026 fair value of approximately $<span id="xdx_902_eus-gaap--EmbeddedDerivativeGainOnEmbeddedDerivative_c20260928__20260928__us-gaap--DebtInstrumentAxis__custom--NoteAOneMember_zIbSvswq0fbb" title="Embedded derivative">62,290</span>. The decrease from its June 30, 2026 fair value of approximately $<span id="xdx_901_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20260630__us-gaap--DebtInstrumentAxis__custom--NoteAOneMember_zjFCv3Isdkxj" title="Fair value of derivatives">107,969</span> resulted in a gain of approximately $<span id="xdx_908_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_c20260630__us-gaap--DebtInstrumentAxis__custom--NoteAOneMember_zQSYa4GOQD72" title="Change in fair value of derivative liability">45,679</span>, which was recognized within “Change in fair value of derivative liability” in the condensed consolidated statements of operations. In connection with the partial extinguishment, approximately $<span id="xdx_90D_eus-gaap--DerivativeLiabilities_iI_c20260928__us-gaap--DebtInstrumentAxis__custom--NoteAOneMember_zaWM7CzE8RW9" title="Derivative liability">27,481</span> of the derivative liability was derecognized, and the remaining derivative liability of approximately $<span id="xdx_902_ecustom--DerivativeLiabilitiesRemaining_iI_c20260928__us-gaap--DebtInstrumentAxis__custom--NoteAOneMember_z2y8lGoMMPti" title="Derivative liability">34,809</span> continued to be recognized in connection with the outstanding portion of the Note A-1.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded approximately $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20260928__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z3qmkJUAOK53" title="Outstanding principal amount">1.2</span> million within stockholders’ equity for the Series B Preferred Stock issued, consisting of approximately $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20260928__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgqOfIEvyMdi" title="Preferred stock, par value">1</span> of par value and approximately $<span id="xdx_902_eus-gaap--PreferredStockIncludingAdditionalPaidInCapital_iI_pn5n6_c20260928_zoZuMPnv89Wg" title="Preferred stock including additional paid in capital">1.2</span> million of additional paid-in capital. Net impact after issuance costs was $<span id="xdx_901_ecustom--StockIssuedDuringPeriodValueIssuanceOfPreferredStockNetOfCostsAndDiscount_c20260928__20260928_zUEu07gzuEml" title="Net issuance costs">1,131,658</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preferred return on the Series B Preferred Stock does not affect net loss until declared or otherwise settled. However, the preferred return accumulated during each reporting period, whether or not declared, is deducted from net loss in determining net loss available to common stockholders and basic and diluted net loss per common share. Any preferred return paid through the issuance of additional Series B Preferred Stock will be reflected as a noncash financing activity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2026, <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9c5p6HnY3Sa" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6k5cOLNqfqc" title="Preferred stock, shares outstanding">120</span></span> shares of Series B Preferred Stock were issued and outstanding, with an aggregate stated value of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn4n6_c20260101__20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z0PJ9NXtdn23" title="Aggregate stated value">1.44</span> million and an aggregate carrying amount of approximately $<span id="xdx_908_eus-gaap--IncreaseInCarryingAmountOfRedeemablePreferredStock_pn5n6_c20260101__20260930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgPrrK4sEuW" title="preferred stock carrying value">1.1</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfDebtTableTextBlock_zlwxH5K5VeD7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt consists of following as of September 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zorSdCF4aOL1" style="display: none">Schedule of Debt</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260930_zZPpOyThfkof" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--NoteAOneMember_zV92ha6YZAMi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 80%">Note A-1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,590,166</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--LongtermDebtTypeAxis__custom--NoteBMember_zHEfAZKRsVH4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Note B</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,000,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DebtInstrumentCarryingAmount_iI_zc0btE5awyxj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total Debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,590,166</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NotesPayableCurrent_iNI_di_zFqUx96y3WH8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: current portion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,344,728</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_zt9ao1Z1Bibl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: unamortized debt discount and issuance costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(360,813</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--LongTermNotesPayable_iI_zDJ2lhzqjD72" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Debt, net of discount and issuance costs</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,884,625</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1590166 5000000 6590166 1344728 360813 4884625 250 0.01 10000 12000 2500000 2720000 5000000 10000000 5000000 5000000 5000000 0.070 If the aggregate outstanding balance of the Note A-1 or the aggregate number of outstanding Preferred Shares is reduced by $2,000,000, the Company will have the right to exchange up to $1,000,000, plus interest (or, if less than $1,000,000, the entire remaining amount of the Note B, or such other amount as the parties mutually agree), of the Note B for a new secured note in the same form and having the same terms as the Note A-1 (each, a “Note Exchange”). Upon the completion of each Note Exchange, an amount of cash equal to the amount of the Note B exchanged in such Note Exchange will be released from the Cash Collateral Account to the Company. The Note A-1 will accrue payment-in-kind (PIK) interest at a rate of 8% per annum, which will be added to the outstanding principal balance of the Note A-1, and will mature 18 months following the Closing Date. 0.05 The Notes can be prepaid by the Company in whole or in part at any time, subject to a 10% prepayment premium on any principal amounts prepaid. Beginning six months after the Closing Date, the Investor may redeem up to $250,000 of the principal amount of the Note A-1 each calendar month. In addition, on any trading day when the Company’s common stock trades at a price that is at least 15% greater than the “Minimum Price” as defined under Nasdaq Stock Market LLC Rule 5635(d), the Investor may redeem an additional principal amount of the Notes equal to 5% of the trading volume of the Company’s common stock on such trading day. The Notes also contain customary events of default, the occurrence of which would permit the Investor to accelerate the obligations under the Notes and exercise remedies against any collateral (including amounts on deposit in the Cash Collateral Account) or guarantees in respect of the Notes. In addition, following the occurrence of an event of default, the interest rate of each Note would increase to the lesser of 15% per year or the maximum rate permitted by applicable law. 350000 292310 <p id="xdx_89A_eus-gaap--InterestIncomeAndInterestExpenseDisclosureTableTextBlock_zL8JOC7IOFkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense consistent of following for nine months ended September 30:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zNrHvKYpNkG4" style="display: none">Schedule of Interest Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260701__20260930_zaO3n6WmfT0i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250701__20250930_zL6IvyuFHaE3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260101__20260930_zoQikwAJDBff" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250101__20250930_zGpHUn6X9Op" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended <br/>September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended <br/>September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--InterestExpenseDebt_hus-gaap--LongtermDebtTypeAxis__custom--NoteAOneMember_zMW9cIaq9aua" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Interest expense on Note A-1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">54,070</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">70,166</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InterestExpenseDebt_hus-gaap--LongtermDebtTypeAxis__custom--NoteBMember_zpwML8FSOvEg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest expense on Note B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64,005</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82,789</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_hus-gaap--LongtermDebtTypeAxis__custom--NoteAOneMember_zOHcLuJwnpCc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortization of debt discount and issuance costs on Note A-1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">122,264</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157,674</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AmortizationOfFinancingCosts_hus-gaap--LongtermDebtTypeAxis__custom--NoteBMember_zg95qe4Hhwi4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Amortization of debt issuance costs - Note B</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">23,794</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30,777</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InterestExpenseNonoperating_z7mx22SHUWT7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">264,133</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">341,406</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 54070 70166 64005 82789 122264 157674 23794 30777 264133 341406 250 0.08 10000 5.0 The Note A-1 contains a limited redemption feature that permits the Investor, beginning six months after closing, to redeem Note A-1 principal on any trading day on which the Company’s common stock trades at or above 115% of the Nasdaq Minimum Price, in an amount up to 5% of the cumulative daily dollar trading volume in aggregate across the outstanding Notes. 130156 34809 67866 45679 1.38 2.461 1.15 2.14 53.46 4.5 68482 2.10 22.84 41177 <p id="xdx_89C_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z077e0st74Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reconciles the derivative liability for the redemption feature of the A-1 Note, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B9_z8skSTsjSHIf" style="display: none">Schedule of Fair Value on Recurring Basis Using Significant Unobservable Inputs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20260101__20260930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DebtInstrumentAxis__custom--NoteAOneMember_zd8kbfd0Ryh8" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--DerivativeLiabilitiesCurrent_iS_z3iTwqD5mNh4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Balance at beginning of period</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1109">–</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--InitialRecognitionUponIssuanceOfDebt_zpPK1ZLJZfU4" style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Initial recognition upon issuance of A-1 Note (June 3, 2026)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">130,156</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DerivativeGainLossOnDerivativeNet_z6iywVaVLHgi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value recognized in earnings ⁽¹⁾</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(67,866</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--DerecognitionUponPartialExtinguishment_zoY6VtZv2frc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Derecognition upon partial extinguishment of A-1 Note</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(27,481</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DerivativeLiabilitiesCurrent_iE_zhqNETS3Nppf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance at end of period</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">34,809</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 130156 -67866 -27481 34809 1200000 120 0.01 10000 12000 0.08 10000 1200000 10000 <p id="xdx_89B_ecustom--ScheduleOfAmountRecognizedInConnectionWithTheExchangeTableTextBlock_zDamYLESCuf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the amounts recognized in connection with the exchange:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zsobsbKGnaK5" style="display: none">Schedule of Amounts Recognized in Connection with the Exchange</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260928__20260928_zJ6QrHOi6Alc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_ecustom--FairValueOfPreferredStockIssued_maGLOEOzk1t_zWIpbHzzVDBc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Fair value of Series B Preferred Stock issued</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,200,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--NetCarryingAmountOfDebtExtinguished_iN_di_msGLOEOzk1t_zauG61VuilPh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net carrying amount of Note A-1 extinguished</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,004,876</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--PortionOfEmbeddedDerivativeLiabilityDerecognized_iN_di_msGLOEOzk1t_zIGoz3T2UkNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Portion of embedded derivative liability derecognized</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(27,481</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_ecustom--LossOnExtinguishmentOfDebt_mtGLOEOzk1t_znmw6frRTSYi" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Loss on extinguishment of Note A-1</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">167,643</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 1200000 1004876 27481 167643 1200000 202000 167643 167643 62290 107969 45679 27481 34809 1200000 1 1200000 1131658 120 120 1440000 1100000 <p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zq5eFL0jICtc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8. <span id="xdx_82D_z7CnvXJ8xeL5">Stockholders’ Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 15, 2024, the Company filed with the U.S. SEC a shelf registration statement on Form S-3 (the “2024 Registration Statement”) for the offer and sale of up to $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn6n6_c20240515__20240515_zqBGv12fk14a" title="Value of securities available for sale">75</span> million of its securities. The 2024 Registration Statement was declared effective on May 22, 2024. The 2024 Registration Statement is intended to provide the Company with flexibility to raise capital in the future for general corporate purposes. On March 23, 2026, the Company filed a prospectus supplement to register an additional $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260323__20260323__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zakxKzU9fhl" title="Stock issued during period, value, new issues">7,000,000</span> of shares of the Company’s common stock issuable pursuant to the At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to the At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the “Sales Agreement”), by and between the Company and H.C. Wainwright &amp; Co., LLC. The Company previously registered the offer and sale of up to $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFfpDNGJ7VG3" title="Sale of stock, consideration received on transaction">10,000,000</span> of shares of Common Stock through the Sales Agent under the Sales Agreement. Upon the filing of Form 10-K for 2025 on March 31, 2026, the Company’s public float was less than $<span id="xdx_904_ecustom--PublicFloatValue_iI_pn6n6_c20260331__srt--RangeAxis__srt--MinimumMember_zDOCTER4eyw8" title="Public float value">75</span> million and as a result, the Company is subject to the limitations contained in General Instruction I.B.6 of Form S-3.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse Stock Split</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 25, 2025, the Company effected a <span id="xdx_902_eus-gaap--StockholdersEquityReverseStockSplit_c20250725__20250725_zsnZNQFv5Hng" title="Reverse stock split">15-for-1 reverse stock split</span> of its common stock which was made effective for trading purposes as of 12:01 a.m. ET on July 25, 2025. As of that date, <span id="xdx_902_eus-gaap--ConversionOfStockDescription_c20250725__20250725_zSIxFYBFSwrf" title="Reverse stock split conversion">each 15 shares of issued and outstanding common stock and equivalents were consolidated into one share of common stock.</span> All shares have been restated to reflect the effects of the <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20250725__20250725_zZIMAbsOFfd9" title="Reverse stock split">15-for-1 reverse stock split</span>. In addition, at the market open on July 25, 2025, the Company’s common stock started trading under a new CUSIP number 15117N701 although the Company’s ticker symbol, IMNN, remained unchanged.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reverse stock split was previously approved by the Company’s stockholders at the 2025 Annual Meeting held on July 11, 2025, and the Company subsequently filed a Certificate of Amendment to its Certificate of Incorporation to affect the stock consolidation. The primary reasons for the reverse stock split and the amendment are:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To provide the Company with the ability to support its anticipated future growth and would provide greater flexibility to consider and respond to future business opportunities and needs as they arise, including equity financings and stock-based acquisitions of new technology and product development candidates. The availability of additional shares of Common Stock would permit the Company to undertake certain of the foregoing actions without delay and expense associated with holding a Special Meeting of Stockholders to obtain stockholder approval each time such an opportunity arises that would require the issuance of shares of Common Stock; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To continue listing on The NASDAQ Capital Market, which requires that the Company comply with the applicable listing requirements under NASDAQ Marketplace Rules, which requirements include, among others, a minimum bid price of at least $<span id="xdx_906_eus-gaap--SharePrice_iI_c20250725_zVJJMLrH4jL7" title="Share price">1.00</span> per share.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately prior to the reverse stock split, the Company had <span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20250724_zduyGHkxPKc" title="Common stock, shares outstanding">31,828,447</span> shares of common stock outstanding which consolidated into <span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20250725_z8j57AToitJa" title="Common stock, shares outstanding">2,121,942</span> shares of the Company’s common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares were rounded up to the nearest whole share. The reverse stock split did not impact the total authorized number of shares of common or preferred stock or the par value thereof. The number of outstanding options, stock awards and warrants were adjusted accordingly, with outstanding options and stock awards being reduced from approximately <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pn5n6_c20250724_zttsd6gUx9S1" title="Options outstanding">1.9</span> million to approximately <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pn5n6_c20250725_zXot88nBnnTc" title="Options outstanding">0.1</span> million and outstanding warrants being reduced from approximately <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pn5n6_c20250724_zngVVPDQ0Suf" title="Warrants outstanding">12.7</span> million to approximately <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pn5n6_c20250725_zRAaB15hTG79" title="Warrants outstanding">0.8</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Increase to Authorized Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company held on July 11, 2025, upon the recommendation of the Company’s board of directors, the Company’s stockholders voted on and approved an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20250710_zluArn65a4oh" title="Number of authorized shares of common stock">112,500,000</span> shares to <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20250711_zhRXl5uSmAPe" title="Common stock, shares authorized">350,000,000</span> shares, and to make a corresponding change to the number of authorized shares of capital stock. Such amendment became effective on July 11, 2025 upon filing with the Secretary of State of the State of Delaware.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Dividend</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 28, 2025, the Company announced that the Company’s Board of Directors approved a <span id="xdx_903_ecustom--StockDividendRatePercentage_iI_pid_dp_uPure_c20250728_z30De6lg63N1" title="Dividend percentage">15</span>% stock dividend, <span id="xdx_904_eus-gaap--CommonStockDividendsPerShareDeclared_c20250728__20260728_zI9bGqFcq3j2" title="Dividend price per share">0.15</span> shares of common stock (the “Stock Dividend”) per share of the Company’s issued and outstanding shares of common stock and per each common stock equivalent with dividend rights.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors fixed August 7, 2025 as the record date (the “Record Date”) for the Stock Dividend, and the Stock Dividend was issued on August 21, 2025 to stockholders of record as of the Record Date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of outstanding warrants were adjusted accordingly, with outstanding warrants increasing from approximately <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pn5n6_c20250725_zrw24DVCjgF5" title="Warrants outstanding">0.8</span> million to approximately <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pn5n6_c20250728_zYOOuCeNJGi4" title="Warrants outstanding">1.0</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>At the Market Offering Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 23, 2026, the Company filed a prospectus supplement registering an additional $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20260323__20260323__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_z9Ximlyjymbh" title="Value of shares available for sale">7,000,000</span> of shares of the Company’s common stock, issuable pursuant to the ATM Agreement.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the first nine months of 2026, the Company sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zDhJiAd2NNE3" title="Number of shares sold">625,480</span> shares of common stock under the ATM Agreement for net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zDwZXzBXoz2c" title="Proceeds from sale of stock">1,292,922</span>. During the first nine months of 2025, the Company sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zQs5r9llNNf3" title="Number of shares sold">744,646</span> shares of common stock under the ATM Agreement for net proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zQeufCec85X6" title="Proceeds from sale of stock">4,530,663</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2026, $<span id="xdx_903_ecustom--ProceedsFromIssuanceOfCommonStockRemained_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_z4w9jD4EBCCg" title="Proceeds from sale of stock remained">10,806,593</span> remained available under the ATM Agreement, subject to the limitations of General Instruction I.B.6 of Form S-3.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>May 2025 Warrant Exchange</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 12, 2025, the Company entered into an exchange agreement (the “Agreement”) with the holders (the “Warrant Holders”) of certain warrants of the Company issued on August 1, 2024, which are exercisable for an aggregate of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250512__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveWarrantExchangeMember_zhz4lSXr0h97" title="Common stock issuable upon exercise">333,334</span> shares of the Company’s common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250512__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveWarrantExchangeMember_zeJfBRHfBJMj" title="Common stock par value">0.01</span> per share. Pursuant to the terms of the Agreement, the Company will issue to the Warrant Holders an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250512__20250512__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveWarrantExchangeMember_zoSu2W2xsip9" title="Shares issued upon exercise of warrants">194,734</span> shares of Common Stock (the “Warrant Exchange Shares”), on a one-for-one basis, in exchange for shares issuable under the Warrants (the “Warrant Exchange”), in reliance on an exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to the Agreement, the Warrant Holders also agreed to waive the Company’s compliance with the provisions of Section 4.12(b) of the Securities Purchase Agreement, dated July 30, 2024, with respect to any Company Variable Rate Transaction (as defined in the Purchase Agreement) for a period of forty-five (45) days from the date of the Agreement and agreed to a lock up period on the Warrant Exchange Shares ending on the opening of trading on May 14, 2025. The Warrant Exchange closed on May 13, 2025. The number of Warrant Exchange Shares that will be issued pursuant to the Agreement will represent <span id="xdx_90B_ecustom--CommonStockOutstandingPercentage_iI_pid_dp_uPure_c20250512__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveWarrantExchangeMember_zsx8Z5m7ZqMa" title="Common stock outstanding percentage">19.98</span>% of the shares of Common Stock outstanding as of the date of the Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>May 2025 Offering</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 23, 2025, the Company entered into a Securities Purchase Agreement with certain institutional and accredited investors, for the issuance and sale in a private placement of (i) <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250523__20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember_z8hsTEjH5BHd" title="Stock issued, shares">185,186</span> shares of the Company’s common stock, (ii) <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zs2j0vw8XkUa" title="Stock issued, shares">296,297</span> of pre-funded warrants at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zh1GkYFV17Z3" title="Warrants exercise price">0.0001</span> per share and (iii) <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSJdpotzcQ73" title="Stock issued, shares">962,964</span> warrants at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM4ElP5jIVb5" title="Warrants exercise price">6.75</span> per share for gross proceeds of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250523__20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember_zvGAOLdlFZ8k" title="Gross proceeds from offering">3.3</span> million before the deduction of placement agent fees and offering expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Prefunded Warrants became exercisable immediately after issuance for a term of two and one-half years following the date of issuance. The Warrants will be exercisable upon receipt of such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity) from the stockholders of the Company with respect to issuance of all of the Warrants and the shares of Common Stock upon the exercise thereof (“Stockholder Approval,” and such date, the “Stockholder Approval Date”) and have a term of three years. The prefunded warrants were exercised in full on June 16, 2025 and June 18, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company issued warrants (the “Placement Agent Warrants”) to H.C. Wainwright &amp; Co., LLC to purchase up to an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentsWarrantMember_zUYshNPxa7ze" title="Stock issued, shares">24,075</span> shares of common stock at an exercise price equal to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentsWarrantMember_zv9kRQH2oZB" title="Share price">8.44</span> per share. The Placement Agent Warrants have substantially the same terms as the Warrants. The closing of the May 2025 Offering occurred on May 28, 2025. On July 11, 2025, the Company’s stockholders approved the issuance of the Warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 2025 Offering</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 29, 2025, the Company entered into a Securities Purchase Agreement (the “December 2025 Purchase Agreement”) with a single healthcare-focused institutional investor (the “Purchaser”) for a registered direct offering (“the December 2025 Offering”) of (i) <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20251229__20251229__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyFiveOfferingMember_z7g5sXARJqgk" title="Number of shares issued">330,000</span> shares of the Company’s common stock, (ii) pre-funded warrants (the “December 2025 Pre-funded Warrants”) in lieu of shares of the Company’s common stock, to the extent the Purchaser so chooses, to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251229__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zQhdE8VgnEn5" title="Warrants issued to purchjase common stock">1,609,114</span> shares of the Company’s common stock (the “Pre-funded Warrant Shares”), and (iii) warrants (the “December 2025 Warrants”) to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251229__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5K18inXfMS7" title="Warrants issued to purchase common stock">1,939,114</span> shares of the Company’s common stock. The closing of the December 2025 Offering was completed on December 31, 2025. The Maxim Group LLC acted as the lead placement agent for the December 2025 Offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-placement agent.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The December 2025 Pre-funded Warrants and Warrants are being sold at a combined offering price of $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20251229__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantAndWarrantsMember_zwVfVqWTYTx5" title="Share price">3.6099</span> per December 2025 Pre-funded Warrant and December 2025 Warrant. The December 2025 Pre-funded Warrants have an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251229__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zvq8MKaUSnyg" title="Warrant price">0.0001</span>, were immediately exercisable and do not have an expiration date. The December 2025 Warrants have an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251229__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9pbhSs2aSoc" title="Warrants exercise price">3.482</span> per share and were immediately exercisable for a term of five years following the date of issuance. <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_pid_c20251229__20251229__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOK3DyznhHD9" title="Warrants exercisable condition">The Company cannot effect the exercise of any December 2025 Pre-funded Warrant or December 2025 Warrant, and a holder will not be entitled to exercise any portion of any December 2025 Pre-funded Warrant or December 2025 Warrant, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder (together with its affiliates) would exceed 9.99% or 4.99%, respectively, of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder’s election upon 61 days’ notice to the Company subject to the terms of such December 2025 Pre-funded Warrants or December 2025 Warrants, provided that such percentage may in no event exceed 19.99%.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received gross proceeds of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20251229__20251229__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--DecemberTwoThousandTwentyFiveOfferingMember_zkQIZQ05HUM5" title="Gross proceeds from offering">7.0</span> million from the December 2025 Offering, before deducting placement agent fees and other offering expenses payable by the Company. The Company plans to use the proceeds from the Offering for general corporate purposes, including research and development activities, capital expenditures and working capital. The December 2025 Purchase Agreement contains customary representations and warranties of the Company, on the one hand, and the Purchaser, on the other hand, and customary conditions to closing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares, pre-funded warrants, and warrants issued and sold to the Purchaser under the December 2025 Purchase Agreement were offered and sold by the Company pursuant to an effective registration statement on Form S-3 (Registration No. 333-279425), as previously filed with and declared effective by the SEC and a related prospectus supplement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 7 for a description of the Series A Preferred Stock issued in connection with the June 2026 Securities Purchase Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 7 for a description of the Series B Preferred Stock issued in connection with the Exchange Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuance of Unregistered Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine-month period ended September 30, 2026, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20260101__20260930__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorMember_zzZKq0cV41ai" title="Number of shares for compensation and fees">157,088</span> shares of common stock to certain officers and directors of the Company in lieu of approximately $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20260101__20260930__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorMember_z0V6oxvWHd3b" title="Value of shares for compensation and fees">278,119</span> in compensation and fees. These shares are unregistered and subject to the rules as outlined in Rule 144.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 75000000 7000000 10000000 75000000 15-for-1 reverse stock split each 15 shares of issued and outstanding common stock and equivalents were consolidated into one share of common stock. 15-for-1 reverse stock split 1.00 31828447 2121942 1900000 100000 12700000 800000 112500000 350000000 0.15 0.15 800000 1000000.0 7000000 625480 1292922 744646 4530663 10806593 333334 0.01 194734 0.1998 185186 296297 0.0001 962964 6.75 3300000 24075 8.44 330000 1609114 1939114 3.6099 0.0001 3.482 The Company cannot effect the exercise of any December 2025 Pre-funded Warrant or December 2025 Warrant, and a holder will not be entitled to exercise any portion of any December 2025 Pre-funded Warrant or December 2025 Warrant, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder (together with its affiliates) would exceed 9.99% or 4.99%, respectively, of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder’s election upon 61 days’ notice to the Company subject to the terms of such December 2025 Pre-funded Warrants or December 2025 Warrants, provided that such percentage may in no event exceed 19.99%. 7000000.0 157088 278119 <p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zpONQfxgFbxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9. <span id="xdx_824_zEMtnVVewLxf">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has long-term compensation plans that permit the granting of equity-based awards in the form of stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, and performance awards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the 2018 Annual Stockholders Meeting of the Company (“ASHM”) held on May 15, 2018, stockholders approved the Imunon, Inc. 2018 Stock Incentive Plan (the “2018 Plan”). The 2018 Plan, as originally adopted, permitted the granting of shares of Imunon common stock as equity awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, performance awards, or in any combination of the foregoing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders have since approved amendments to the 2018 Plan at the 2019 ASHM held on May 14, 2019, the 2020 ASHM held on June 15, 2020, the 2021 ASHM held on June 10, 2021, the 2023 ASHM held on June 14, 2023, the 2025 ASHM held on July 11, 2025 and at the 2026 ASHM held on June 16, 2026. As of September 30, 2026, a total of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanMember_zotcnmhl1jtk" title="Awards approved for issuance">1,264,665</span> awards have been approved by the Company’s shareholders for issuance under the 2018 Plan, as amended. Following is a schedule of the stock awards approved to the 2018 Plan, as amended:</span></p> <p id="xdx_899_ecustom--ScheduleOfAnnualStockholdersMeetingPlanAmendmentsTableTextBlock_zPzSqqe431A" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zU8ti429HAIc" style="display: none">Schedule of 2018 ASHM Plan Amendments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholder</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approval Event</b></span></p></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2018 Plan (as adopted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>and amended)</b></span></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards Approved</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cumulative</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards Approved</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 24%; text-align: center">2018 ASHM</td><td style="width: 2%"> </td> <td style="width: 24%; text-align: center">2018 Plan Adoption</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 21%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAdoptionMember_z2rwTulj7LZ8" title="Number of awards approved">12,000</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 21%; text-align: right"><span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAdoptionMember_z00fPUifWA9f" title="Common stock, reserved for future issuance">12,000</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2019 ASHM</td><td> </td> <td style="text-align: center">Amendment #1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentOneMember_z6iHYSr32o41" title="Number of awards approved">5,333</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentOneMember_zykGVaGauxH6" title="Common stock, reserved for future issuance">17,333</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">2020 ASHM</td><td> </td> <td style="text-align: center">Amendment #2</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentTwoMember_zbrDz1NM9uGb" title="Number of awards approved">11,111</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentTwoMember_zgbyJ9ViBzxd" title="Common stock, reserved for future issuance">28,444</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2021 ASHM</td><td> </td> <td style="text-align: center">Amendment #3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentThreeMember_zUhGCfwZDD04" title="Number of awards approved">34,222</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentThreeMember_zywCKnb5cqHb" title="Common stock, reserved for future issuance">62,666</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">2023 ASHM</td><td> </td> <td style="text-align: center">Amendment #4</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentFourMember_zjUtndyIsVj3" title="Number of awards approved">68,666</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentFourMember_zb7DiiGKDNKa" title="Common stock, reserved for future issuance">131,332</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2025 ASHM</td><td> </td> <td style="text-align: center">Amendment #5</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentFiveMember_zUNz0BZ8JLkc" title="Number of awards approved">133,333</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentFiveMember_z4h4lhpwjjnh" title="Common stock, reserved for future issuance">264,665</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">2026 ASHM</td><td> </td> <td style="text-align: center">Amendment #6</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentSixMember_zmV94AazjBWe" title="Number of awards approved">1,000,000</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentSixMember_z0RPoetrzFGg" title="Cumulative awards approved">1,264,665</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A3_zfR1T4qdwpzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has issued stock awards to employees, officers and directors in the form of stock options, restricted stock and common stock. <span id="xdx_908_ecustom--StockOptionsStrikePriceDescription_c20260101__20260930__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_zV1Cjsgil9R3" title="Stock options, strike price description">Stock options are generally granted with strike prices equal to the fair market value of a share of Imunon common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of the Company must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option and restricted stock awards vest upon terms determined by the Compensation Committee of the Board of Directors and are subject to accelerated vesting in the event of a change of control or certain terminations of employment. The Company issues new shares to satisfy its obligations from the exercise of options or the grant of restricted stock awards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total compensation cost related to stock options and restricted stock awards was approximately $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20260101__20260930__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionAndRestrictedStockAwardsMember_zKkysDJh6EL7" title="Share based compensation">0.7</span> million and $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250930__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionAndRestrictedStockAwardsMember_z54xXCABZOgc" title="Share based compensation">0.1</span> million of expense for the nine months ended September 30, 2026 and 2025, respectively. Of these amounts, approximately $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20260101__20260930__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionAndRestrictedStockAwardsMember__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--ResearchAndDevelopmentExpense_zt4c6km87qxa" title="Share based compensation expense">0.2</span> million and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20260101__20260930__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionAndRestrictedStockAwardsMember__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zsGAjzO0vY9e" title="Share based compensation expense">0.5</span> million for the nine months ended September 30, 2026 were charged to research and development expenses and general and administrative expenses, respectively, compared to $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20250930__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionAndRestrictedStockAwardsMember__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--ResearchAndDevelopmentExpense_zn4kes23DFQl" title="Share based compensation expense">29,000</span> and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250930__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionAndRestrictedStockAwardsMember__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zN0UA6Gsf7tb" title="Stock compensation cost">0.1</span> million for the same periods of 2025 charged to research and development expenses and administrative expenses, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine-month period ended September 30, 2026, the Company also issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_c20260101__20260930_z7D3TmE1BCQa" title="Number of shares issued for bonus payment">399,624</span> shares of common stock to employees in payment for $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_c20260101__20260930_z4D1pHi7UDR8" title="Value of shares issued for bonus payment">687,375</span> compensation including remaining bonuses accrued for 2025. A summary of stock option awards and restricted stock grants for the nine months ended September 30, 2026 is presented below:</span></p> <p id="xdx_89A_ecustom--SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock_zgvlGNTQrfed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> <span id="xdx_8BE_zEIiPSlcrOwk" style="display: none">Schedule of Stock Options Awards and Restricted Stock Grants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Options</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Weighted</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Options</p> <p style="margin-top: 0; margin-bottom: 0">Outstanding</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p> <p style="margin-top: 0; margin-bottom: 0">Average</p> <p style="margin-top: 0; margin-bottom: 0">Exercise</p> <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0">Average</p> <p style="margin-top: 0; margin-bottom: 0">Contractual</p> <p style="margin-top: 0; margin-bottom: 0">Terms of</p> <p style="margin-top: 0; margin-bottom: 0">Equity Awards</p> <p style="margin-top: 0; margin-bottom: 0">(in years)</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Stock options outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zA82wXpvv0Pd" style="width: 13%; text-align: right" title="Options outstanding, beginning balance">18,695</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMrr7wnw0mhi" style="width: 13%; text-align: right" title="Weighted average exercise price, beginning balance">15.68</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zS8ptnYDnY8i" style="text-align: right" title="Options, granted">242,364</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOaq3qH1w7X9" style="text-align: right" title="Weighted average exercise price, granted">3.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Stock options terminated</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv6zMF96523h" style="border-bottom: Black 1pt solid; text-align: right" title="Options, terminated">(2,413</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5fAKVfrmNA7" style="padding-bottom: 1pt; text-align: right" title="Equity awards terminated">4.31</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Stock options outstanding at September 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z823gV8MZQP6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending balance">258,646</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX5ipZYPb7Hi" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, ending balance">4.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPY3mfpJtxd6" title="Weighted average contractual terms">9.5</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at September 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqxnWJCNCHLh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, exercisable">135,560</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlKwAdRYwY91" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, exercisable">5.42</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGRkAYAA3mD1" title="Weighted average contractual terms, exercisable">9.4</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Aggregate intrinsic value of stock options exercisable at September 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zz2rITSg2t8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1357">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zvA9qV0pLXX2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2026, there were approximately <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260930__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_zc2yCqd4Scw7" title="Shares remaining for issuance">606,734</span> shares remaining for issuance under the 2018 Plan, as amended. As of September 30, 2026, there was a total of $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20260930_zbmAwpYnjSd8" title="Unrecognized compensation cost">0.3</span> million unrecognized compensation cost related to non-vested stock-based compensation arrangements. That cost is expected to be recognized over a period of <span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20260101__20260930_zydoXLaY3nbj" title="Cost recognized period">0.8</span> years. The weighted average grant date fair values of the stock options granted were $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260930_zTAaC7UzNpRa" title="Weighted average grant date fair value per share">3.74 </span>during the nine-month period ended September 30, 2026</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from the Company’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zJ5PJix83L9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zTa1vmK0zdBh">Schedule of Assumptions Used to Determine Fair Value of Options Granted</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended September 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260930_zkNL0dilq2q8" title="Risk-free interest rate">4.19</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20250930_zS7qnvZ0EAIb" title="Risk-free interest rate, minimum">4.22</span>% to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20250930_zTyjs4OVLrB3" title="Risk-free interest rate, maximum">4.55</span></span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260930_zLlJBzCQSpJ3" title="Expected volatility">123</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20250930_zJZgKBslQtll" title="Expected volatility, minimum">111</span> to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20250930_zHvO5cKYm21j" title="Expected volatility, maximum">123</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260930_zehtPb7s13o8" title="Expected life (in years)">9.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MinimumMember_zePl4Em90THb" title="Expected life (in years)">9.0</span> to <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MaximumMember_zfN7m42uaD8f" title="Expected life (in years)">10.0</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20260101__20260930_zRu2PJRzyzWe" style="text-align: right" title="Expected dividend yield">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250930_zjaCmmEkLbB" style="text-align: right" title="Expected dividend yield">0.0</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AA_zKIvVAdGZRwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatilities utilized in the model are based on historical volatility of the Company’s stock price. The risk-free interest rate is derived from values assigned to U.S. Treasury bonds with terms that approximate the expected option lives in effect at the time of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1264665 <p id="xdx_899_ecustom--ScheduleOfAnnualStockholdersMeetingPlanAmendmentsTableTextBlock_zPzSqqe431A" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zU8ti429HAIc" style="display: none">Schedule of 2018 ASHM Plan Amendments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholder</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approval Event</b></span></p></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2018 Plan (as adopted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>and amended)</b></span></p></td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards Approved</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cumulative</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards Approved</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 24%; text-align: center">2018 ASHM</td><td style="width: 2%"> </td> <td style="width: 24%; text-align: center">2018 Plan Adoption</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 21%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAdoptionMember_z2rwTulj7LZ8" title="Number of awards approved">12,000</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 21%; text-align: right"><span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAdoptionMember_z00fPUifWA9f" title="Common stock, reserved for future issuance">12,000</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2019 ASHM</td><td> </td> <td style="text-align: center">Amendment #1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentOneMember_z6iHYSr32o41" title="Number of awards approved">5,333</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentOneMember_zykGVaGauxH6" title="Common stock, reserved for future issuance">17,333</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">2020 ASHM</td><td> </td> <td style="text-align: center">Amendment #2</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentTwoMember_zbrDz1NM9uGb" title="Number of awards approved">11,111</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentTwoMember_zgbyJ9ViBzxd" title="Common stock, reserved for future issuance">28,444</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2021 ASHM</td><td> </td> <td style="text-align: center">Amendment #3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentThreeMember_zUhGCfwZDD04" title="Number of awards approved">34,222</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentThreeMember_zywCKnb5cqHb" title="Common stock, reserved for future issuance">62,666</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">2023 ASHM</td><td> </td> <td style="text-align: center">Amendment #4</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentFourMember_zjUtndyIsVj3" title="Number of awards approved">68,666</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentFourMember_zb7DiiGKDNKa" title="Common stock, reserved for future issuance">131,332</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2025 ASHM</td><td> </td> <td style="text-align: center">Amendment #5</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentFiveMember_zUNz0BZ8JLkc" title="Number of awards approved">133,333</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentFiveMember_z4h4lhpwjjnh" title="Common stock, reserved for future issuance">264,665</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">2026 ASHM</td><td> </td> <td style="text-align: center">Amendment #6</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentSixMember_zmV94AazjBWe" title="Number of awards approved">1,000,000</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAmendmentSixMember_z0RPoetrzFGg" title="Cumulative awards approved">1,264,665</span></td><td style="text-align: left"> </td></tr> </table> 12000 12000 5333 17333 11111 28444 34222 62666 68666 131332 133333 264665 1000000 1264665 Stock options are generally granted with strike prices equal to the fair market value of a share of Imunon common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of the Company must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options. 700000 100000 200000 500000 29000000 100000 399624 687375 <p id="xdx_89A_ecustom--SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock_zgvlGNTQrfed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> <span id="xdx_8BE_zEIiPSlcrOwk" style="display: none">Schedule of Stock Options Awards and Restricted Stock Grants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Options</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Weighted</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Options</p> <p style="margin-top: 0; margin-bottom: 0">Outstanding</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p> <p style="margin-top: 0; margin-bottom: 0">Average</p> <p style="margin-top: 0; margin-bottom: 0">Exercise</p> <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0">Average</p> <p style="margin-top: 0; margin-bottom: 0">Contractual</p> <p style="margin-top: 0; margin-bottom: 0">Terms of</p> <p style="margin-top: 0; margin-bottom: 0">Equity Awards</p> <p style="margin-top: 0; margin-bottom: 0">(in years)</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Stock options outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zA82wXpvv0Pd" style="width: 13%; text-align: right" title="Options outstanding, beginning balance">18,695</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMrr7wnw0mhi" style="width: 13%; text-align: right" title="Weighted average exercise price, beginning balance">15.68</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zS8ptnYDnY8i" style="text-align: right" title="Options, granted">242,364</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOaq3qH1w7X9" style="text-align: right" title="Weighted average exercise price, granted">3.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Stock options terminated</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv6zMF96523h" style="border-bottom: Black 1pt solid; text-align: right" title="Options, terminated">(2,413</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5fAKVfrmNA7" style="padding-bottom: 1pt; text-align: right" title="Equity awards terminated">4.31</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Stock options outstanding at September 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z823gV8MZQP6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending balance">258,646</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX5ipZYPb7Hi" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, ending balance">4.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPY3mfpJtxd6" title="Weighted average contractual terms">9.5</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at September 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqxnWJCNCHLh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, exercisable">135,560</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlKwAdRYwY91" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, exercisable">5.42</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGRkAYAA3mD1" title="Weighted average contractual terms, exercisable">9.4</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Aggregate intrinsic value of stock options exercisable at September 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zz2rITSg2t8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1357">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 18695 15.68 242364 3.95 2413 4.31 258646 4.31 P9Y6M 135560 5.42 P9Y4M24D 606734 300000 P0Y9M18D 3.74 <p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zJ5PJix83L9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zTa1vmK0zdBh">Schedule of Assumptions Used to Determine Fair Value of Options Granted</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended September 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20260101__20260930_zkNL0dilq2q8" title="Risk-free interest rate">4.19</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20250930_zS7qnvZ0EAIb" title="Risk-free interest rate, minimum">4.22</span>% to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20250930_zTyjs4OVLrB3" title="Risk-free interest rate, maximum">4.55</span></span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260930_zLlJBzCQSpJ3" title="Expected volatility">123</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20250930_zJZgKBslQtll" title="Expected volatility, minimum">111</span> to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20250930_zHvO5cKYm21j" title="Expected volatility, maximum">123</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260930_zehtPb7s13o8" title="Expected life (in years)">9.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MinimumMember_zePl4Em90THb" title="Expected life (in years)">9.0</span> to <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MaximumMember_zfN7m42uaD8f" title="Expected life (in years)">10.0</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20260101__20260930_zRu2PJRzyzWe" style="text-align: right" title="Expected dividend yield">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250930_zjaCmmEkLbB" style="text-align: right" title="Expected dividend yield">0.0</td><td style="text-align: left">%</td></tr> </table> 0.0419 0.0422 0.0455 1.23 1.11 1.23 P9Y P9Y P10Y 0.000 0.000 <p id="xdx_805_ecustom--WarrantsTextBlock_zwJRYQki87Ij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10. <span id="xdx_82B_zfMvOeD4AKW7">Warrants</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zwU8F8YWCt55" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following is a summary of all warrant activity for the nine-month period ended September 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zOTPyJbez0zb">Summary of Warrant Activity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left">Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Number of</p> <p style="margin-top: 0; margin-bottom: 0">Warrants Issued</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Weighted Average</p> <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants outstanding at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20260101__20260930_zgpGbIPD1nE5" style="width: 16%; text-align: right" title="Warrants outstanding, Beginning balance">4,513,475</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260930_zDSwjZtwDqtc" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Beginning balance">5.04</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Pre-funded warrants exercised during the nine months ended September 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesPrefundedWarrantsExercised_iN_di_c20260101__20260930_zkHHABn26RP3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Pre-funded warrants exercised">(1,609,114</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodsWeightedAverageExercisePriceWeightedAverageExercisePricePrefundedWarrantsExercised_c20260101__20260930_zTLHaIQOmZD1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Pre-funded warrants exercised">0.0001</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Warrants outstanding at September 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20260101__20260930_zvVe3H7KBIGl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, Ending balance">2,904,361</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260930_zZztZyYDoaSc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Ending balance">5.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average remaining contractual terms at September 30, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260930_fKGEp_zXYICahgMf38">3.5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A6_z8pHI8zgSaBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zwU8F8YWCt55" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following is a summary of all warrant activity for the nine-month period ended September 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zOTPyJbez0zb">Summary of Warrant Activity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left">Warrants</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Number of</p> <p style="margin-top: 0; margin-bottom: 0">Warrants Issued</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Weighted Average</p> <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants outstanding at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20260101__20260930_zgpGbIPD1nE5" style="width: 16%; text-align: right" title="Warrants outstanding, Beginning balance">4,513,475</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260930_zDSwjZtwDqtc" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Beginning balance">5.04</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Pre-funded warrants exercised during the nine months ended September 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesPrefundedWarrantsExercised_iN_di_c20260101__20260930_zkHHABn26RP3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Pre-funded warrants exercised">(1,609,114</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodsWeightedAverageExercisePriceWeightedAverageExercisePricePrefundedWarrantsExercised_c20260101__20260930_zTLHaIQOmZD1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Pre-funded warrants exercised">0.0001</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Warrants outstanding at September 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20260101__20260930_zvVe3H7KBIGl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, Ending balance">2,904,361</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260930_zZztZyYDoaSc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Ending balance">5.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average remaining contractual terms at September 30, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260930_fKGEp_zXYICahgMf38">3.5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> 4513475 5.04 1609114 0.0001 2904361 5.04 P3Y6M <p id="xdx_808_eus-gaap--LesseeOperatingLeasesTextBlock_zCNvgFqy6Mc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11. <span id="xdx_82D_zwHj4OcQ6lab">Leases </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lawrenceville, New Jersey Lease</i></b> - In August 2023, the Company renewed its Lawrenceville office lease for a <span id="xdx_902_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20230831__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember_zWXWpdnZGQb8" title="Operating lease, term">24</span>-month agreement for <span id="xdx_90E_eus-gaap--AreaOfLand_iI_pp0p0_usqrt_c20230831__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember_zLF6akE82gA5" title="Area of land">9,850</span> square feet with monthly rent payments of approximately $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20230801__20230831__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember__srt--RangeAxis__srt--MinimumMember_zZBTkmcPLdMb" title="Payments for rent">22,983</span> to $<span id="xdx_90C_eus-gaap--PaymentsForRent_pp0p0_c20230801__20230831__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember__srt--RangeAxis__srt--MaximumMember_zX4hIWEySQwj" title="Payments for rent">23,394</span>. In April 2025, the Company renewed its Lawrenceville office lease until November 30, 2028 for <span id="xdx_90A_eus-gaap--AreaOfLand_iI_pp0p0_usqrt_c20250430__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember_zq4cYrVW7DEi" title="Area of land">4,359</span> square feet (to be reduced to <span id="xdx_909_eus-gaap--AreaOfLand_iI_pp0p0_usqrt_c20260401__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember_zkaa70cQOs" title="Area of land">4,011</span> following April 1, 2026) with monthly rent payments of approximately $<span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20250401__20250430__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember__srt--RangeAxis__srt--MinimumMember_zTesAqZw86R6" title="Payments for rent">10,361</span> to $<span id="xdx_904_eus-gaap--PaymentsForRent_pp0p0_c20250401__20250430__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember__srt--RangeAxis__srt--MaximumMember_zr65C534rH38" title="Payments for rent">10,863</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Huntsville, Alabama Lease</i></b> - In January 2023, the Company renewed its Huntsville facility lease for a <span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20230131__us-gaap--TypeOfArrangementAxis__custom--HuntsvilleAlabamaLeaseMember_z8nKbCSw7aOh" title="Operating lease, term">60</span>-month lease agreement for <span id="xdx_905_eus-gaap--AreaOfLand_iI_pp0p0_usqrt_c20230131__us-gaap--TypeOfArrangementAxis__custom--HuntsvilleAlabamaLeaseMember_zzJN5NLt7sO3" title="Area of land">11,420</span> square feet with monthly rent payments of approximately $<span id="xdx_90B_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230131__us-gaap--TypeOfArrangementAxis__custom--HuntsvilleAlabamaLeaseMember__srt--RangeAxis__srt--MinimumMember_z4nk7R9ZNvOd" title="Payments for rent">28,550</span> to $<span id="xdx_90D_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230131__us-gaap--TypeOfArrangementAxis__custom--HuntsvilleAlabamaLeaseMember__srt--RangeAxis__srt--MaximumMember_zJ0nndYnAAOh" title="Payments for rent">30,903</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zvjbJn1Id204" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a table of the lease payments and maturity of the Company’s operating lease liabilities as of September 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zHD1eekidYf3">Schedule of Lease Payments and Maturity of Operating Lease Liabilities</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20260930_znUFSODz5SUh" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzy9p_zIHFeOITgPu4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Remainder of 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">122,479</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzy9p_zIwtlGNCQtW5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">498,086</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzy9p_zbSgxhHDK6wc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,896</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_maLOLLPzy9p_znAtYhrAmTm8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2029 and thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1442">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzy9p_z6JEhEwjv2d8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Subtotal future lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">770,461</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zXdRQAx2QR86" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(62,364</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_z4AeXY1GN054" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">708,097</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average remaining life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260930_zZrdrGvZaFR6" title="Operating lease, weighted average remaining lease term">1.63</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260930_zwoBf4RJTJGi" style="text-align: right" title="Operating lease, weighted average discount rate, percent">9.98</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A0_zznp3cCnyiNj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine-month period ended September 30, 2026, operating lease expense was $<span id="xdx_90D_eus-gaap--OperatingLeaseCost_pp0p0_c20260101__20260930_zCCzRKrqUCD6" title="Operating lease, cost">362,745</span> and cash paid for operating leases included in operating cash flows was $<span id="xdx_90E_eus-gaap--OperatingLeasePayments_pp0p0_c20260101__20260930_zg94iFyaDdLh" title="Operating lease, payments">366,342</span>. For the nine-month period ended September 30, 2025, operating lease expense was $<span id="xdx_90D_eus-gaap--OperatingLeaseCost_pp0p0_c20250101__20250930_ziuVCYiuq9fi" title="Operating lease expense">402,384</span> and cash paid for operating leases included in operating cash flows was $<span id="xdx_90A_eus-gaap--OperatingLeasePayments_pp0p0_c20250101__20250930_z7duHMTornyk" title="Cash paid for operating leases included in operating cash flows">400,936</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P24M 9850 22983 23394 4359 4011 10361 10863 P60M 11420 28550 30903 <p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zvjbJn1Id204" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a table of the lease payments and maturity of the Company’s operating lease liabilities as of September 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zHD1eekidYf3">Schedule of Lease Payments and Maturity of Operating Lease Liabilities</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20260930_znUFSODz5SUh" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzy9p_zIHFeOITgPu4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Remainder of 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">122,479</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzy9p_zIwtlGNCQtW5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">498,086</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzy9p_zbSgxhHDK6wc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,896</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_maLOLLPzy9p_znAtYhrAmTm8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2029 and thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1442">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzy9p_z6JEhEwjv2d8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Subtotal future lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">770,461</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zXdRQAx2QR86" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(62,364</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_z4AeXY1GN054" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">708,097</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average remaining life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260930_zZrdrGvZaFR6" title="Operating lease, weighted average remaining lease term">1.63</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20260930_zwoBf4RJTJGi" style="text-align: right" title="Operating lease, weighted average discount rate, percent">9.98</td><td style="text-align: left">%</td></tr> </table> 122479 498086 149896 770461 62364 708097 P1Y7M17D 0.0998 362745 366342 402384 400936 <p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zyf4qgscs2cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12. <span id="xdx_82B_zzvwPBUkpeJk">Commitments and Contingencies </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are not currently a party to any material legal proceedings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_z7h2Eq4zNkt4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13. <span id="xdx_82A_zfq1zvq3Z0Hg">Subsequent Events </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated its subsequent events from September 30, 2026 and through the date these unaudited condensed consolidated financial statements were issued, determining all subsequent events have been disclosed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sale of ThermoDox</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 20, 2026, Imunon entered into an Asset Purchase Agreement with VoxelDox Therapeutics, Inc. (“VoxelDox”), pursuant to which the Company agreed to sell to VoxelDox the Company’s assets relating to ThermoDox®, a heat-activated liposomal formulation of doxorubicin (the “Purchased Assets”), including related trademarks, regulatory filings, clinical and preclinical data, manufacturing know-how and existing drug product vials. VoxelDox intends to develop ThermoDox for glioblastoma and other high-grade gliomas. The transaction is contingent on VoxelDox raising at least $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20261020__20261020__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__dei--LegalEntityAxis__custom--VoxelDoxTherapeuticsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSvD6bsQOSni" title="Sale of stock transaction contingent">2.5</span> million. If it does not raise this funding, the transaction will not close and the Company will receive no consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the transaction closes, VoxelDox will issue to the Company shares of VoxelDox common stock equal to <span id="xdx_900_ecustom--DilutedCapitalizationPercentage_iI_pid_dp_uPure_c20261020__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQyhlrj21rE2" title="Diluted capitalization percentage">4.76</span>% of its fully diluted capitalization. VoxelDox will also pay the Company up to $<span id="xdx_907_ecustom--MilestonePayments_pn5n6_c20261020__20261020__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__dei--LegalEntityAxis__custom--VoxelDoxTherapeuticsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6zslsX6uUla" title="Milestone payments">16.5</span> million in milestone payments upon the achievement of specified clinical and regulatory milestones, including initiation of a Phase 3 clinical trial of ThermoDox and FDA acceptance and approval of a New Drug Application. In addition, VoxelDox will pay royalties on annual net sales. If VoxelDox determines in good faith that the transferred ThermoDox vials are not usable, milestone payments and royalty rates will be reduced by 50%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until VoxelDox completes a qualified equity financing, the Company may appoint one of VoxelDox’s five directors and one non-voting observer. The Purchase Agreement contains customary representations, warranties, covenants and indemnification provisions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to VoxelDox board approval and separate consulting agreements, VoxelDox will grant Michael H. Tardugno, the Company’s Executive Chairman, and Frederick J. Fritz, a member of the Company’s Board of Directors, shares of VoxelDox common stock each equal to <span id="xdx_90A_ecustom--DilutedCapitalizationPercentage_iI_pid_dp_uPure_c20261020__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_z1LVw3N0HEtj" title="Diluted capitalization percentage">2.38</span>% of its fully diluted capitalization, vesting monthly over 36 months, for consulting services to VoxelDox. Other than as described above, there is no material relationship between the Company and VoxelDox.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2026 Financing</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 27, 2026, the Company filed a registration statement on Form S-1 (File No. 333-299647) with the SEC, as amended on October 28, 2026, for a proposed best-efforts public offering. The offering covers up to <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20261027__20261027__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBGM4D328o4g" title="Number of common stock issued">20,000,000</span> shares of common stock, or pre-funded warrants in lieu thereof, together with common warrants to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20261027__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4lfTHZosWH1" title="Common stock exchange of warrants">70,000,000</span> shares of common stock or exchange warrants in lieu thereof. Maxim Group LLC is acting as placement agent. The registration statement reflects an assumed combined public offering price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20261027__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKm5D616bZvd" title="Share issued price per share">1.25</span> per share of common stock and accompanying warrants (or $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20261027__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zarQHT5qQAnc" title="Warrant price per share">1.2499</span> per pre-funded warrant and accompanying warrants), representing maximum assumed gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20261027__20261027__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zc9KWqya4VH4" title="Gross proceeds">25.0</span> million before placement-agent fees and offering expenses. The proposed offering has no minimum offering requirement, remains subject to pricing, market and closing conditions, the SEC declaring the registration statement effective, and may be completed for fewer than all securities offered or not at all. As of November 12, 2026, the proposed offering had not been completed and no proceeds had been received. No amounts relating to the proposed offering have been recognized in the accompanying unaudited condensed consolidated financial statements.</span></p> 2500000 0.0476 16500000 0.0238 20000000 70000000 1.25 1.2499 25000000.0 false false false false false false Includes issuance cost of $68,342 incurred in cash for series B preferred stock issued in exchange of Note A-1 payable presented as part of cash from financing activities.